Introduction {#s1}
============

Obesity and its associated diseases such as diabetes and hypertension affect a high percentage of the world population ([@bib84]). Excess fat mass in obese individuals is driven by an increase in adipocyte cell size (hypertrophy) or number (hyperplasia) ([@bib72]; [@bib60]). A comprehensive knowledge of adipocyte differentiation is therefore relevant and timely both from a basic and medical research perspective. Adipocytes arise from multipotent mesenchymal stem cells (MSCs) through an initial lineage commitment phase, followed by terminal differentiation with accumulation of lipid droplets ([@bib8]). Although many of the key transcription factors (TFs) controlling this adipogenic program are known, a cohesive model of the underlying molecular events has yet to be revealed.

Most of our current understanding of adipogenesis has been derived using the in vitro murine committed pre-adipocyte cell line 3T3-L1 ([@bib20], [@bib21]), which to a certain extent recapitulates key features of adipogenesis ([@bib22]). The adipocyte differentiation program is accomplished by the expression and activity of a cascade of TFs (reviewed in \[[@bib59]; [@bib61]; [@bib15]; [@bib58]; [@bib64]\]), most notably the early-expressed CCAAT/enhancer binding proteins beta (C/EBPβ) and delta (C/EBPδ), which induce C/EBPα and the adipogenic master regulator nuclear hormone receptor peroxisome proliferator-activated receptor gamma (PPARγ). C/EBPα and PPARγ cooperate to activate adipogenic genes and cross-regulate each other in a positive feedback loop to maintain the terminally differentiated state of mature adipocytes ([@bib88]).

Several studies have revealed the importance of other TFs in regulating adipogenesis both in vitro and in vivo ([@bib70]). These include members of the Krüppel-like family (KLF4 \[[@bib7]\], KLF5 \[[@bib51]\], and KLF15 \[[@bib46]\]), ADD1/SREBP1c ([@bib13]; [@bib39]), the E2F ([@bib14]), and the interferon regulatory factor (IRF) families ([@bib11]), STAT5A/B ([@bib16]) and GATA2/3 ([@bib77]). Efforts are therefore underway to integrate this information into comprehensive adipogenic regulatory networks (aGRNs) ([@bib58], [@bib66]), to which new nodes such as the early regulators ZFP432 ([@bib26]), TCF7L1 ([@bib10]), or EVI1 ([@bib32]) keep being added. This suggests that many important components of this aGRN remain to be discovered.

To systematically identify novel aGRN members, we performed a large-scale overexpression screen with 734 full-length mouse TFs in 3T3-L1 cells, which led to the identification of 26 pro-adipogenic TFs. We found that the top ranking TF, ZEB1, previously known for its role in epithelial to mesenchymal transition (EMT) and tumor metastasis ([@bib82]; [@bib19]), is a critical mediator of in vitro and in vivo adipogenesis, as it directly controls the majority of aGRN genes.

Results {#s2}
=======

A large-scale TF overexpression screen identifies novel positive regulators of adipogenesis {#s2-1}
-------------------------------------------------------------------------------------------

To systematically identify TFs enhancing adipogenesis in an unbiased manner, we tested the effect of overexpressing almost half (48%) of all predicted mouse TFs on 3T3-L1 fat cell differentiation. We transferred 750 available mouse TF open reading frames (ORFs) ([@bib25]) into Tet-On Gateway-compatible inducible lentiviral expression vectors and obtained 734 clones ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Using a robotic platform, lentiviral particles containing each TF ORF were produced and were then used to transduce 3T3-L1 cells with three replicates to ensure reproducibility. We overexpressed each of the 734 TFs in 3T3-L1 cells at confluence and during terminal adipocyte differentiation ('Materials and methods'; [Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). After 7 days, we stained cells for lipids with the lipophilic, fluorescent dye BODIPY, nuclei with Hoechst, and complete cells with SYTO60 and calculated the percentage of mature adipocytes per total number of cells in each well using automated image analysis as described previously ([@bib44]) ([Figure 1A](#fig1){ref-type="fig"} and 'Materials and methods'). Using this approach, we were able to define the percentage of cells that had undergone differentiation (percentage of differentiated cells, PDC), which was used to evaluate the impact of each tested TF on adipogenesis.10.7554/eLife.03346.003Figure 1.A large-scale TF overexpression screen identifies novel positive regulators of adipogenesis.(**A**) Schematic overview of high-throughput screening illustrating how 3T3-L1 cells were transduced with 734 individual TFs in three replicates each, 3 days before induction of adipocyte differentiation ('Materials and methods'). The effect of TF overexpression was quantified at differentiation day 7 by lipid, nucleus and cellular staining and summarized as a percentage of differentiated cells (PDC) per TF. (**B**) Overview of fold-changes (FC) compared to control for all TFs showing a differentiation FC \> 1. TFs that significantly induced differentiation (FC ≥ 1.5, α = 0.05) are highlighted in red and PPARγ specifically in orange. (**C**) Effect of stably overexpressing eight putatively novel regulators of adipogenesis, PPARγ, or a control vector on 3T3-L1 differentiation as assessed by Oil Red O staining of lipid droplets at day 5 after induction. (**D**) Effect of knocking down ZEB1 or PPARγ (as a positive control), or the negative control (empty shRNA) on 3T3-L1 differentiation as assessed by Oil Red O staining at day 6 after induction. In the shRNA pool of ZEB1, shRNA2 was not used because the robustness of the cells after treatment was low. Examples of microscopic images illustrating the overexpression or knockdown (KD) effects on 3T3-L1 differentiation are shown in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} or [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}, respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.03346.003](10.7554/eLife.03346.003)10.7554/eLife.03346.004Figure 1---figure supplement 1.Large-scale TF overexpression screen identifies novel positive regulators of adipogenesis.(**A**) Workflow for transferring mouse TF open reading frames (ORFs) into a lentiviral vector to overexpress HA-tagged TFs in 3T3-L1 cells. 750 fully sequence-verified entry TF clones were transferred using LR Gateway cloning into the Tet-On expression vector (derived from the original TRE_GOI_rtTA_hPGK vector \[[@bib5]\], 'Materials and methods'), during which the attL sites recombine with the attR sites. 734 ORF TFs were successfully transferred. (**B**) Barplots: percentage of expressed/transcribed TFs of all TFs that significantly enhance adipogenesis (positive candidates) in mouse 3T3-L1 cells based on microarray expression data in mouse 3T3-L1 (mExpr) and human hASC (hExpr) as well as POLII signal over genes (mPolII) and combined POLII signal and expression (mAny) in mouse 3T3-L1 cells ([@bib49]; [@bib45]); table: positive candidates that are significantly up- or down-regulated in mouse adipose tissue compared to other probed tissues based on ArrayExpress Expression Atlas ([@bib35]). (**C**) Protein levels of stably overexpressed HA-tagged TFs selected for follow-up in 3T3-L1 cells (follow-up TFs). The expected molecular mass for each protein is indicated above the image. Note that especially for ZEB1, several bands were detected which likely correspond to cryptic translation or specific protein degradation products given that they stem from the same open-reading frame construct and that they are all tagged by HA. (**D**--**F**) Relative (to control): *Pparg2* (**D**), *Cebpa* (**E**), and *Adipoq* (**F**) mRNA fold-changes (FCs) in 3T3-L1 cells stably overexpressing each follow-up TF, as measured by qPCR. To measure *Pparg2 mRNA* levels, primers were used that target the 5′ UTR of the endogenous transcript, allowing us to differentiate between the overexpression and endogenous *Pparg* transcripts. (**G**) Microarray-based ([@bib45]) expression analysis of follow-up TFs during 3T3-L1 adipogenesis. In contrast to *Pparg* (orange), most follow-up TFs are at their maximal expression level already prior to induction of differentiation (days −2 and day 0). (**H**) Relative (to control; i.e. transduced with the shEmpty vector) *Zeb1* mRNA FCs in knockdown 3T3-L1 cells at four different time points during adipogenesis, as measured by qPCR. Error bars depict the standard error of the mean from three biological replicate experiments. \*\*p ≤ 0.01 and 0.01 \< \*p ≤ 0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.03346.004](10.7554/eLife.03346.004)10.7554/eLife.03346.005Figure 1---figure supplement 2.Microscopic images of Oil Red O stained 3T3-L1 adipocytes after overexpression of candidate TFs.These images were acquired from the wells presented in [Figure 1C](#fig1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.03346.005](10.7554/eLife.03346.005)10.7554/eLife.03346.006Figure 1---figure supplement 3.Microscopic images of Oil Red O stained 3T3-L1 adipocytes after ZEB1 and PPARG KD using distinct KD constructs.These images were acquired from the wells presented in [Figure 1D.](#fig1){ref-type="fig"}**DOI:** [http://dx.doi.org/10.7554/eLife.03346.006](10.7554/eLife.03346.006)

Specifically, we compared the PDC obtained for each TF to that of the negative control (original lentiviral vector). We found 26 TFs that significantly enhance adipogenesis (≥ 1.5-fold relative to control (FC), Bonferroni \< 0.05) of which 22 have to our knowledge never been implicated in this process, with the TF ZEB1 showing the strongest effects ([Supplementary file 1A](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\] and [Figure 1B](#fig1){ref-type="fig"}). Importantly, the master regulator PPARγ was among these 26 stringently selected top ranking candidates, serving as a positive control.

Because our screen was blind to the expression and functional characteristics of the overexpressed TFs, we investigated which of our top enhancing TFs are also endogenously expressed in 3T3-L1 cells or other pre-adipocyte cell lines. For this purpose, we analyzed publicly available microarray expression data from mouse 3T3-L1 and primary human adipose stromal cells, as well as RNA polymerase II (POLII) binding data for expressed TFs ([@bib49]; [@bib45]). We found that 18 of the top 26 candidates (69%) show high microarray signal or POLII gene body occupancy, suggesting that they are actively transcribed during 3T3-L1 differentiation ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}, [Supplementary file 1A](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\] and 'Materials and methods'). Additionally, we found using Expression Atlas ([@bib35]) that nine of the positive candidates (including PPARγ and the top candidate ZEB1) are expressed significantly higher in adipose tissue compared to their mean expression across tissues ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). The high abundance of these TFs may point to a regulatory function in adipocyte-specific processes. Moreover, 15 (83%) of the candidates\' human orthologs are also highly expressed in human adipose stromal cells ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}), suggesting that their regulation is conserved.

To validate the adipogenic activity of our newly identified pro-adipogenic TFs, we generated 10 stably transduced 3T3-L1 cell lines, including for eight of the top candidates that were not previously implicated in adipogenesis (referred to as 'follow-up TFs'), as well as for PPARγ and the negative control vector, using puromycin selection. TFs were overexpressed for 2 days before inducing differentiation, and lipids were stained with Oil Red O 5 days after differentiation. Overexpression of the TFs was confirmed by Western blots ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Compared with cells transduced with the control vector, overexpression of 6 out of these 8 TFs led to increased lipid content within the respective cells ([Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}) and a strong induction of adipogenic gene expression as measured by quantitative real-time polymerase chain reaction (qPCR) (*Pparg2*, *Cebpa*, and *Adipoq*) after differentiation ([Figure 1---figure supplement 1D--F](#fig1s1){ref-type="fig"}). Interestingly, all but one of these six follow-up TFs were expressed at their maximal level in wild-type 3T3-L1 cells already at the onset of adipogenesis (day −2 or day 0), in contrast to *Pparg*, which is highly induced upon differentiation ([@bib78]) ([Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"} and [Supplementary file 1A](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\]). This suggests that these TFs may be important in defining the pre-adipocyte state and may act as early regulators of fat cell differentiation.

To confirm the involvement of the top differentiation-enhancing TF ZEB1 in 3T3-L1 adipogenesis, we reduced its expression levels with three distinct shRNAs. In parallel, shRNAs targeting *Pparg* were used as a positive control. After transducing each shRNA into 3T3-L1 cells, we induced differentiation and stained for lipid accumulation at day 6. The pooled knockdown (KD) reduced *Zeb1* gene expression during adipogenesis by approximately 80--90% ([Figure 1---figure supplement 1H](#fig1s1){ref-type="fig"}). Oil Red O staining revealed a dramatic reduction in differentiation for individual shRNAs and an almost completely abolished differentiation when the shRNA pool was used, an effect that mimicked that of PPARγ KD ([Figure 1D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}).

Thus, we identified several TFs that increase adipogenesis when transiently or stably overexpressed in 3T3-L1 cells ([Figure 1B--C](#fig1){ref-type="fig"}). In addition, we revealed that KD of the top adipogenic candidate ZEB1 inhibits adipogenesis in 3T3-L1 cells ([Figure 1D](#fig1){ref-type="fig"}), suggesting that this TF is a so far unrecognized, important mediator of 3T3-L1 fat cell differentiation.

Alteration of nuclear ZEB1 levels perturbs the expression of adipogenic regulators and pathways {#s2-2}
-----------------------------------------------------------------------------------------------

To explore the mechanism underlying ZEB1-induced stimulation of adipogenesis, we used 3T3-L1 cells. First, we quantified its expression level by qPCR at six adipogenic differentiation time points ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Unlike *Pparγ*, whose expression is highly induced upon adipogenesis ([@bib78]), *Zeb1* mRNA levels were already high in pre-adipocytes and moderately but significantly decreased during terminal differentiation ([Figure 2---figure supplement 1A--B](#fig2s1){ref-type="fig"}, p = 0.009, Wilcoxon rank-sum test days −2 to 2 vs. day 4). This result is consistent with data from previously published microarray-based gene expression during adipogenesis ([@bib45]) as well as with data comparing pre-adipocyte to adipocyte gene expression (Expression Atlas: \[[@bib35]\]) ([Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"} and [Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). ZEB1 may thus already be active at early stages of adipogenesis, in line with the observation that it is among several genes that were highly upregulated immediately after adipogenic induction of mouse embryonic stem cells ([@bib6]).

We next examined ZEB1 protein levels during differentiation using our recently developed quantitative proteomics assay ([@bib68]). We found that ZEB1 is expressed at comparable levels to the nuclear receptor RXRα at day 0 (about 0.25 fmol/μg nuclear extract) (\[[@bib68]\] and [Figure 2A](#fig2){ref-type="fig"}). We observed a ZEB1 protein increase of about 1.4- to 2.1-fold at day 2 compared to day 0 after which ZEB1 decreased to intermediate levels ([Figure 2A](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}). These results indicate that, even though ZEB1 is already highly expressed in pre-adipocytes, its nuclear protein level tends to further increase over the course of differentiation, which appears consistent with the enhancing effect of ZEB1 upon overexpression. This effect may be explained through post-transcriptional regulation.10.7554/eLife.03346.007Figure 2.ZEB1 knockdown perturbs the expression of adipogenic regulators.(**A**) Protein levels (fmol/μg nuclear extract) of ZEB1 during 3T3-L1 differentiation (one representative biological replicate). (**B**) *Pparg2* and *Cebpa* mRNA levels after ZEB1 knockdown and overexpression in un-induced 3T3-L1 pre-adipocytes as measured by qPCR. (**C**) Expression levels \[ln(FPKM), 'Materials and methods'\] of mouse genes in ZEB1 KD vs. control cells at day 0 and day 2 after differentiation induction as measured by RNA-seq. Significantly up-regulated genes (FC ≥ 1.5, *padj* ≤ 0.01) are highlighted in blue, down-regulated genes in orange (FC ≤ 0.67, *padj* ≤ 0.01), significantly de-regulated follow-up TFs as well as adipogenic TFs such as PPARγ and C/EBPs are indicated in black. Bar plots represent the percentage of genes that are significantly up- or down-regulated. Representative enriched GeneGO pathway categories for up- or down-regulated genes are highlighted (complete results in [Supplementary file 1C](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\]). (**D**) Number of significantly up- or down-regulated genes belonging to previously defined expression clusters (High/7/4/3) ([@bib45]). The typical expression pattern of genes in each cluster as well as of representative members that are significantly down-regulated upon ZEB1 KD is sketched. Clusters are sorted by increasing enrichment of down-regulated genes and corresponding p-values (chi-square test) are listed. (**E**) Distribution of gene expression FCs at day 0 after ZEB1 KD for genes annotated as positive or negative regulators of adipogenesis ([Supplementary file 1B](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\]). Error bars depict the standard error of the mean. \*\*p ≤ 0.01 and 0.01 \< \*p ≤ 0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.03346.007](10.7554/eLife.03346.007)10.7554/eLife.03346.008Figure 2---figure supplement 1.ZEB1 knockdown perturbs the expression of adipogenic regulators.(**A**) Relative (to day −2) *Zeb1* mRNA levels in wild-type 3T3-L1 cells during differentiation, as measured by qPCR. (**B**) Raw Ct values for *Pparg*, *Zeb1* as well as the housekeeping gene *HPRT1* at days 0 and 4 of 3T3-L1 differentiation as measured by qPCR. (**C**) *Pparg* and *Zeb1* mRNA levels in pre-adipocytes and adipocytes derived from publicly available data through ArrayExpress ([@bib62]). (**D**) Protein levels (fmol/μg nuclear extract) of ZEB1 during 3T3-L1 differentiation (biological replicate of data shown in [Figure 2A](#fig2){ref-type="fig"}). (**E**) *Pparg2* and *Cebpa* mRNA levels after ZEB1 knockdown and overexpression at day 4 after adipogenic induction as measured by qPCR. (**F**) Fold-changes of expression levels of selected adipogenic factors in response to ZEB1 KD as measured by qPCR and RNA-seq at day 0 and day 2 of 3T3-L1 differentiation. The Pearson\'s correlation coefficient (r) is indicated. (**G**) Number of significantly up- and down-regulated genes after ZEB1 knockdown belonging to previously defined expression clusters (2/5/Low/1) ([@bib45]). The typical expression pattern of genes in each cluster is sketched. Clusters are sorted by decreasing enrichment of up-regulated genes and corresponding p-values (chi-square test) are listed. (**H**) Changes in mRNA levels and POLII binding over gene bodies after ZEB1 and SMRT knockdown, respectively ([@bib55]). The Spearman\'s ρ is indicated, showing a significantly negative correlation. (**I**) Percent of genes with dynamic SMRT binding during adipogenesis (red), of genes that lose/gain POLII upon SMRT KD (red), and of random genes (grey) that are significantly differentially expressed upon ZEB1 KD. Error bars depict the standard error of the mean. \*\*p ≤ 0.01 and 0.01\< \*p ≤ 0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.03346.008](10.7554/eLife.03346.008)

We next assessed whether the expression of key adipogenic transcriptional regulators is sensitive to nuclear ZEB1 levels. Indeed, ZEB1 overexpression increases *Pparg2* and *Cebpa* levels already in pre-adipocytes and later after induction of differentiation at day 4 ([Figure 2B](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}). Conversely, reducing ZEB1 levels prevents *Pparg2* and *Cebpa* induction as measured at day 4, and significantly reduces their expression in pre-adipocytes ([Figure 2B](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}). To gain global insights into gene expression alterations upon ZEB1 KD, we performed replicate RNA-seq experiments in control and ZEB1 KD cells prior to differentiation (day 0) and 2 days after the onset of differentiation ('Materials and methods'). As expected, *Zeb1* mRNA levels were significantly reduced in both data sets ([Figure 2C](#fig2){ref-type="fig"}, FC cutoff 1.5 and *padj* ≤ 0.01). Further, the expression fold-changes of several adipogenic TFs and markers measured by qPCR and RNA-seq were highly correlated (Pearson\'s r ≥ 0.95; [Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}), validating expression estimates obtained by RNA-seq.

In total, 3,426 (17% of all expressed) and 3,221 (16% of all expressed) genes were significantly de-regulated in ZEB1 KD cells compared to control samples at day 0 and day 2, respectively ([Figure 2C](#fig2){ref-type="fig"} and [Supplementary file 1B](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\]). We observed no difference between the fractions of genes that are significantly up- or down-regulated after KD ([Figure 2C](#fig2){ref-type="fig"}), consistent with a summarizing report indicating that the regulatory function of ZEB1 is versatile and may be context-dependent ([@bib19]), although indirect regulatory effects cannot be excluded.

Genes down-regulated upon ZEB1 KD as measured at day 2 are enriched for fat-cell-specific pathways such as 'Putative pathways for stimulation of fat cell differentiation by Bisphenol A', 'Role of Diethylhexyl Phthalate and Tributyltin in fat cell differentiation' and 'RXR-dependent regulation of lipid metabolism via PPAR, RAR, and VDR' ([Figure 2C](#fig2){ref-type="fig"} and [Supplementary file 1C](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\]). Pathway enrichment analysis of genes whose expression changed already in pre-adipocytes revealed a clear distinction between up- and down-regulated genes. While the former enriched for cell cycle and cytoskeleton remodeling-related processes, the latter singled out various developmental pathways previously implicated in adipogenesis ([@bib33]), including 'TGF-beta-dependent induction of EMT via SMADs', 'Ligand-dependent activation of the ESR1/AP1 pathway', 'WNT signaling pathway Part 2', and 'Notch Signaling Pathway' ([Figure 2C](#fig2){ref-type="fig"} and [Supplementary file 1C](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\]). Specifically, reducing ZEB1 expression in 3T3-L1 cells had a strong impact on the expression of the adipogenic master regulators *Cebpa*, *Cebpd* as well as the known adipogenic TFs *Nr3c1* and *Krox20* ([Supplementary file 1B](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\] and [Figure 2C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}). Moreover, we found that the expression of four novel adipogenic candidates identified in the TF screen (*Zfp30*, *Ebf3*, *Msx1*, and *Atoh8*) is equally perturbed (at day 0) by reduced ZEB1 levels, suggesting that they may belong to the same regulatory module ([Figure 2C](#fig2){ref-type="fig"} and [Supplementary file 1B](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\]).

To better understand the gene regulatory function of ZEB1, we analyzed the proportion of up- and down-regulated genes in each of nine distinct gene clusters that were previously derived from genome-wide microarray-based expression data generated during 3T3-L1 terminal differentiation ([@bib45]). Strikingly, genes showing decreased expression upon confluence under normal conditions (i.e., expression at day −2 is higher than at day 0) were significantly up-regulated at day 0 in ZEB1 KD cells ([Figure 2---figure supplement 1G](#fig2s1){ref-type="fig"}). The enrichment was strongest for genes in cluster 2, which were previously associated with mitosis and cell cycle functions. This is consistent with the pathway analysis results reported above and suggests that ZEB1 may control the expression of genes involved in coordinated cell cycle arrest, an essential step in 3T3-L1 differentiation ([@bib74]). Conversely, we found that a striking majority of genes whose expression increases upon confluence (day −2 expression lower than day 0 expression) were downregulated at day 0 upon ZEB1 KD ([Figure 2D](#fig2){ref-type="fig"}). The strongest signal was observed for cluster 3 genes, which were previously associated with cell adhesion and extracellular matrix functionality. We note that several other EMT factors such as *Snai2* (previously shown to be a promoter of adipogenesis \[[@bib52]\]), *Twist1, Id2* and *Id3* fall in this cluster and were significantly down-regulated upon ZEB1 KD.

To test how ZEB1 KD specifically impacts the expression of known adipogenic TFs in a statistical threshold-independent manner, we directly compared expression fold-changes of positive and negative regulators ([Supplementary file 1B](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\]) of fat cell differentiation ([Figure 2E](#fig2){ref-type="fig"}). In pre-adipocytes, positive regulators tended to be down-regulated upon ZEB1 KD while negative regulators were up-regulated (p = 0.007, Wilcoxon rank-sum test comparing fold-changes), suggesting that ZEB1 acts primarily as a positive regulator in the context of the aGRN, consistent with observations from our phenotype-profiling experiments. We recently dissected the role of SMRT (NCOR2), a transcriptional co-repressor, in fat cell differentiation and showed how it maintains genes in a poised state until adipogenesis is induced ([@bib55]). If ZEB1 is, as hypothesized, an activator of early adipogenic genes, which are partially repressed by SMRT, we expect (1) a high overlap between genes regulated by SMRT and ZEB1; and (2) SMRT and ZEB1 KD to have inverse effects on the expression of the genes that they control. Indeed, we found that the fold-changes induced in POLII binding upon SMRT KD and in gene expression upon ZEB1 KD were significantly negatively correlated (Spearman\'s ρ = −0.36, p \< 10^−16^) ([Figure 2---figure supplement 1H](#fig2s1){ref-type="fig"}). For example, while SMRT KD significantly increased POLII levels at the positive adipogenic regulators *Cebpa* and *Id4* ([@bib47]), ZEB1 KD highly reduced their mRNA levels in pre-adipocytes. Overall, we found that over 40% (compared to an expected 14%) of both the genes that lose SMRT binding upon fat cell differentiation and those that experience a POLII binding change upon SMRT KD are significantly (p \< 0.004 Fisher\'s exact test and permutation test) de-regulated upon ZEB1 KD ([Figure 2---figure supplement 1I](#fig2s1){ref-type="fig"}).

Collectively, these results provide molecular evidence that ZEB1 is required for the adipogenic transcriptional program by controlling mRNA levels of a broad range of genes during adipogenesis. Specifically, ZEB1 promotes the expression of established key adipogenic regulators such as PPARγ and C/EBPα, and balances against pathways that repress and in favor of those that mediate terminal differentiation.

ZEB1 co-binds adipogenic regulatory regions with established early regulators such as C/EBPβ {#s2-3}
--------------------------------------------------------------------------------------------

To delineate the direct transcriptional effects of ZEB1 from other indirect layers of regulation, we next performed ZEB1 ChIP-seq in 3T3-L1 pre-adipocytes ('Materials and methods'). Replicate experiments including a pull-down with anti-HA in ZEB1-HA overexpressing 3T3-L1 cells showed high ChIP enrichment compared to negative controls as well as high correlation of read counts (Spearman\'s ρ ≥ 0.83) ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A--C](#fig3s1){ref-type="fig"}). ZEB1 exhibited widespread DNA binding (27,854 target regions), including at the genomic locus of the adipogenic master regulator *Pparg* ([Figure 3A--B](#fig3){ref-type="fig"}). We note that ZEB1 preferentially bound gene-proximal locations, with almost 25% of ZEB1 targets overlapping TSSs and the vast majority of regions located within 10 kb of an annotated gene ([Figure 3B](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"} for comparison with random regions, POLII, and C/EBPβ distribution). The association of ZEB1 with promoters as well as with CpG islands and exonic regions is highly significant at a genome-wide scale (p \< 10^−16^, [Supplementary file 1D](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\]).10.7554/eLife.03346.009Figure 3.ZEB1 co-binds the genome with established adipogenic regulators such as C/EBPβ.(**A**) ZEB1, C/EBPβ, POLII, and Control (CTRL) read density tracks at the *Pparg* locus. (**B**) Number of ZEB1-bound regions and of their proximal (≤ 10 kb) genes in 3T3-L1 cells. Distribution of ZEB1 binding with respect to genomic annotation ('Materials and methods'). (**C**) De novo motif discovery using MEME and a 50 bp sequence centered on ZEB1 peak summits reveals the canonical ZEB1 motif (p = 10^−8^, 'Materials and methods') (**D**) Motif enrichment analysis in a 100 bp window around ZEB1 peak summits reveals 138 significantly enriched motifs (complete results in [Supplementary file 1E](#SD1-data){ref-type="supplementary-material"}). Highlighted here are motif names of the known early adipogenic regulators C/EBPβ, NFI, and AP1 factors as well as RUNX and SMAD3. (**E**) Peak overlap between ZEB1 and C/EBPβ (day 0) as well as AP1 factors (day 0, 4 hr) in 3T3-L1 cells. (**F**) Overview of ZEB1, C/EBPβ, AP1 proteins ATF2 and ATF7, POLII normalized ChIP-seq as well as DNase-seq (DHS) enrichments ('Materials and methods') in a 2 kb window around the summits of ZEB1 peaks that overlap C/EBPβ binding. Intervals are sorted based on decreasing ZEB1 enrichment. (**G**) Summarized results from mass spectrometry experiments of proteins that were identified when pulling down ZEB1 (complete results in [Supplementary file 1F](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\]).**DOI:** [http://dx.doi.org/10.7554/eLife.03346.009](10.7554/eLife.03346.009)10.7554/eLife.03346.010Figure 3---figure supplement 1.ZEB1 co-binds the genome with established adipogenic regulators such as C/EBPβ.(**A**) ZEB1 ChIP-qPCR validation of ChIP-seq data at 12 selected ZEB1 target sites and three negative control (CTRL) regions during 3T3-L1 adipogenesis. (**B**) Scatterplot and Spearman\'s ρ of ZEB1 ChIP-seq and ZEB1-HA ChIP-seq read counts inside genomic intervals defined by ZEB1 binding in pre-adipocytes. (**C**) Spearman correlations between read counts for replicate ZEB1 ChIP-seq (including ZEB1-HA) as well as publicly available POLII and DNase-seq data ([@bib65]; [@bib55]) inside genomic intervals defined by ZEB1 binding in pre-adipocytes. (**D**) Distribution of randomly shifted ZEB1, C/EBPβ, and POLII peaks with respect to genomic annotation ('Materials and methods'). (**E**) ZEB1 motif density at 800 bp centered on ZEB1 peak summits. (**F**) Fraction of ZEB1 and randomly shifted ZEB1 peaks (to show background values) that contain at least one or two, respectively, ZEB1, CACCTG (E-box), C/EBPβ, AP1, NFIC and SMAD3 motif hits ('Materials and methods'). (**G**) Peak overlap between randomly shifted ZEB1 and C/EBPβ bound regions in 3T3-L1 pre-adipocytes. (**H**) Overview of ZEB1, ZEB1-HA, C/EBPβ, AP1 factors ATF2 and ATF7, POLII and H3K9AC normalized ChIP-seq as well as DNase-seq and control (CTRL) enrichments ('Materials and methods') in a 2 kb window around the summits of ZEB1 peaks. Intervals are sorted based on decreasing ZEB1 enrichment. (**I**) Mean C/EBPβ and AP1 complex proteins JUN and FOSL normalized (to total read number) ChIP-seq enrichments in human HepG2 and lymphoblastoid cell lines (LCLs) in a 8 kb window around the summits of ZEB1 peaks detected in LCLs.**DOI:** [http://dx.doi.org/10.7554/eLife.03346.010](10.7554/eLife.03346.010)10.7554/eLife.03346.011Figure 3---figure supplement 2.ZEB1 binding and expression is affected by C/EBPβ KD.(**A**) C/EBPβ expression (mRNA level) in stable C/EBPβ KD and control 3T3-L1 pre-adipocytes as measured by qPCR. (**B**) C/EBPβ ChIP-qPCR at 10 C/EBPβ-ZEB1, 6 ZEB1-only and six negative control regions according to our ZEB1 D0 ChIP-seq data and publicly available C/EBPβ ChIP-seq data ([@bib65]). 5 out of 6 ZEB1-only regions also show C/EBPβ ChIP enrichment. \*C/EBPβ-enriched regions (**C**) ZEB1 ChIP-qPCR at 9 C/EBPβ-ZEB1 regions as well as one ZEB1-only region (10) in C/EBPβ KD and control 3T3-L1 cells. \* regions showing changes in ZEB1 enrichment after C/EBPβ KD (**D**) *Zeb1* expression (mRNA level) in stable C/EBPβ KD and control 3T3-L1 cells as measured by qPCR. (**E**) POLII, ZEB1, and C/EBPβ read density tracks at the *Zeb1* locus in 3T3-L1 pre-adipocytes.**DOI:** [http://dx.doi.org/10.7554/eLife.03346.011](10.7554/eLife.03346.011)

De novo motif analysis using 50 bp around the ZEB1 peak summit ([Figure 3C](#fig3){ref-type="fig"}) revealed a top-scoring motif that strongly matched MA0103.2 (TOMTOM p=10^−8^), which was previously annotated as the ZEB1 position weight matrix (PWM) in Jaspar ([@bib27]) ([Figure 3C](#fig3){ref-type="fig"}). Although the ZEB1 motif was preferentially located proximal to the point of highest ZEB1 ChIP enrichment ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}), only a subset (24%) of ZEB1-bound regions contained such a motif match ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}). To discover additional enriched sequence patterns of ZEB1-bound regions, we extended the motif search to 100 bp around the peak summit. We obtained a large list of significantly enriched motifs ([Supplementary file 1E](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\]), including AP1\|Jun-AP1, NF1, RUNX, C/EBPβ, and SMAD3 motifs (p ≤ 10^−12^) ([Figure 3D](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}), of which several occurred multiple times within the same ZEB1-bound region ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}). Together, these results suggest that, while there is sequence specificity to ZEB1 binding, the protein is most likely recruited to a broad number of regulatory regions, either by or in cooperation with other DNA binding proteins.

To verify whether ZEB1 targets previously identified (pre)adipogenic regulatory regions, we used publicly available C/EBPβ and AP1 binding data in 3T3-L1 cells ([@bib65]; [@bib67]). We found that almost one third of ZEB1-bound regions were co-bound by C/EBPβ, which represents a significant enrichment over random expectation (Fisher\'s exact test, p ≤ 10^−12^) ([Figure 3E](#fig3){ref-type="fig"}). Both ZEB1 and C/EBPβ ChIP-seq signal intensities were high at these 5,032 genomic locations, which were also enriched for AP1 factor binding (in particular ATF7 and ATF2), high DNase I signal, and to a lesser extent POLII ([Figure 3F](#fig3){ref-type="fig"}). Strikingly, 27% of regions bound by ZEB1 at day 0 were also bound by at least one of the five AP1 complex proteins JUNB, FOSL2, CJUN, ATF7, and ATF2 4 hr after induction of differentiation, again a highly significant co-localization (Fisher\'s exact test, p ≤ 10--12) ([Figure 3E](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1G](#fig3s1){ref-type="fig"}). Globally, regions showing higher ZEB1 enrichment co-localized more with TF binding and with genomic marks of transcriptional activity such as POLII and H3K9AC as well as open chromatic regions as indicated by high DNase I signal intensity ([Figure 3---figure supplement 1H](#fig3s1){ref-type="fig"}). Indeed, genome-wide correlations between ZEB1 and POLII ChIP-seq read counts were high ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). Finally, we also analyzed the overlap between ZEB1, AP1, and C/EBPβ in the human HepG2 as well as lymphoblastoid cell lines (LCLs) (data from ENCODE \[[@bib18]\]). We observed consistent enrichment of C/EBPβ, JUN, and FOSL (AP1 complex members) around ZEB1 peak summits ([Figure 3---figure supplement 1I](#fig3s1){ref-type="fig"}), providing support for a conserved molecular relationship between these TFs in mediating DNA binding.

To test whether the observed genomic co-localization of ZEB1, C/EBPβ, and AP1 factors relies on physical interactions, we assayed ZEB1 interaction partners in 3T3-L1 cells by mass spectrometry ([Figure 3G](#fig3){ref-type="fig"} and [Supplementary file 1F](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\]). We first verified that we could recover the ZEB1 protein as well as its known interaction partners such as CtBP1/2 and HDAC1/2 ([@bib19]). The presence of these four known partners among the 89 stringently selected ('Materials and methods') and reproducibly pulled down proteins confirmed the validity of our approach. Importantly, we also detected C/EBPβ at similar stringency and additionally, RUNX2, NFIX, and AP1-family members ATF2 and ATF7-specific peptides in one of the replicate experiments ([Figure 3G](#fig3){ref-type="fig"}). These data suggest that, in 3T3-L1 cells, ZEB1 is located within the same protein complex as at least one of the major regulators of adipogenic gene expression (C/EBPβ) and potentially also cooperates with other adipogenic TFs such as ATF2 or ATF7 to mediate transcription.

To further assess the functional relationship between ZEB1 and C/EBPβ binding, we performed ZEB1 ChIP experiments after stable C/EBPβ knockdown in 3T3-L1 cells ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}), testing 10 ZEB1-C/EBPβ co-bound regions, six ZEB1-only regions, and six negative control regions ([Supplementary file 1I](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\]) based on our ZEB1 and publicly available C/EBPβ ChIP-seq data ([@bib65]). We first validated these C/EBPβ-bound regions by performing C/EBPβ ChIP-qPCR in our (control) 3T3-L1 cells ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}). We found that C/EBPβ was almost invariably enriched at ZEB1-bound regions, even at regions (five out of six) that did not show C/EBPβ enrichment in the publicly available ChIP-seq data and that were thus presumed to be bound by ZEB1 only ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}). Thus, the genomic co-localization of the two proteins may be even more widespread than originally appreciated, strengthening their functional relationship. In stable C/EBPβ knockdown cells, we observed a decrease of both C/EBPβ and ZEB1 DNA binding at the majority of the tested regions with the exception of the single ZEB1-only bound region, suggesting that ZEB1 DNA-binding is dependent on C/EBPβ ([Figure 3---figure supplement 2C](#fig3s2){ref-type="fig"}). However, when we measured *Zeb1* mRNA levels in the C/EBPβ KD cells, we observed a two-fold decrease compared to control ([Figure 3---figure supplement 2D](#fig3s2){ref-type="fig"}). This result implies that C/EBPβ mediates *Zeb1* expression, which is substantiated by the fact that C/EBPβ directly targets the *Zeb1* gene in 3T3-L1 pre-adipocytes ([Figure 3---figure supplement 2E](#fig3s2){ref-type="fig"}). Thus, at this point, we cannot exclude that the observed decrease in ZEB1 DNA binding in C/EBPβ KD cells may in part be a consequence of decreased cellular ZEB1 levels. Further experiments will be required to examine putative DNA binding cooperativity effects between these two TFs.

Collectively, these observations demonstrate that in committed pre-adipocytes, ZEB1 is bound to open/active regulatory regions already before the onset of adipogenesis. Many of these regions are targeted by first-wave adipogenic TFs such as C/EBPβ and AP1-family members, implying a functional relationship between these TFs and, given the provided evidence, especially between ZEB1 and C/EBPβ in early adipogenic regulatory events.

ZEB1 DNA binding is dynamic at adipogenic genes {#s2-4}
-----------------------------------------------

To better understand the dynamic regulatory properties of ZEB1, we profiled its DNA binding during 3T3-L1 fat cell differentiation by including days −2, 2, and 4 in addition to day 0. The vast majority of ZEB1-bound regions (42,050) showed consistent enrichment across all time points ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}), reflected in high correlations among samples (Spearman\'s ρ ≥ 0.75 day 4 vs. any other day; [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). However, ZEB1 binding profiles prior to (days −2 and 0, subsequently referred to as 'early') and post (days 2 and 4, referred to as 'late') differentiation induction were more similar to one another, respectively, forming two distinct clusters ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). Globally, we detected 552 early-only and 803 late-only ZEB1-bound regions (FC ≥ 2, FDR 0.1, [Figure 4A--B](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A,C](#fig4s1){ref-type="fig"}, 'Materials and methods'). Interestingly, genomic loci of several adipogenic regulators, including *Pparg, Klf15*, and *Zbtb16* ([@bib45]; [@bib2]) contained regions with increased ZEB1 binding after differentiation induction ([Supplementary file 1B](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\], [Figure 4A](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}).10.7554/eLife.03346.012Figure 4.ZEB1 binding increases at adipogenic genes during 3T3-L1 differentiation.(**A**) ZEB1 and POLII read density tracks at the *Klf15* locus during 3T3-L1 differentiation (days −2, 0, 2, and 4). Late-only bound regions are highlighted. (**B**) ZEB1, C/EBPβ, RXRα, PPARγ, POLII normalized ChIP ('Materials and methods') as well as DHS enrichments in a 2 kb window around the summits of late-only (days 2 and 4 but not days −2 and 0; *padj* ≤ 0.1, FC ≥ 2) ZEB1-bound regions during 3T3-L1 differentiation. (**C**) Differential motif discovery using MEME and a 50 bp sequence centered on summits of late-only vs. static ZEB1 peaks reveals adipogenic motifs: C/EBPα\|C/EBPβ, NFIC and PPARG::RXR (p \< 10^−3^, 'Materials and methods'). (**D**) GREAT-based ([@bib43]) Gene Ontology enrichment analysis of genes associated with late-only vs. static ZEB1 binding reveals terms associated with fat cell differentiation and function (complete results in [Supplementary file 1G](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\]). (**E**) Fraction of genes associated with late-only ZEB1 binding and fraction of all genes significantly up (blue) and down (orange)-regulated after ZEB1 KD as measured at differentiation day 2 (complete results in [Figure 4---figure supplement 1G](#fig4s1){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.03346.012](10.7554/eLife.03346.012)10.7554/eLife.03346.013Figure 4---figure supplement 1.ZEB1 binding increases at adipogenic genes during differentiation.(**A**) Overview of ZEB1, C/EBPβ, RXRα, PPARγ, POLII normalized ChIP-seq as well as DNase-seq enrichments ('Materials and methods') in a 2 kb window around the summits of static (*padj* ≥ 0.1 or FC \< 2) and early-only (days-2 and 0 but not days 2 and 4; *padj* ≤ 0.1, FC ≥ 2) ZEB1-bound regions during 3T3-L1 differentiation. (**B**) Spearman correlations between read counts for ZEB1 ChIP-seq data at distinct adipogenic time points (days −2, 0, 2, and 4) inside genomic intervals defined by ZEB1 binding at any of these time points. (**C**) ZEB1 and POLII read density tracks at the *Zbtb16* and *Pparg* loci during 3T3-L1 differentiation (days-2, 0, 2, and 4). Summarized genome-wide results are included in [Supplementary file 1G](#SD1-data){ref-type="supplementary-material"}. (**D**) Differential motif discovery using MEME and a 50 bp sequence centered on summits of early-only vs static ZEB1 peaks reveals non-adipogenic motifs: RUNX1/2 and TEAD1 (p \< 10^−5^, 'Materials and methods'). (**E**) GREAT-based ([@bib43]) Gene Ontology enrichment analysis of genes associated with early-only vs static ZEB1 binding reveals terms associated with chemokine secretion and non-adipogenic functions. Full results are displayed in [Supplementary file 1G](#SD1-data){ref-type="supplementary-material"}. (**F**) Number of significantly up- or down-regulated genes associated (≤10 kb) with at least one early-only or late-only ZEB1 bound region, respectively, belonging to previously defined expression clusters (1/Low/7/5) ([@bib45]). The typical expression pattern of genes in each cluster is sketched. Clusters are sorted by increasing enrichment of late-only ZEB1-bound genes and corresponding p-values (chi-square test) are listed. Only clusters showing a highly significant p-value (p \< 10^−10^) are shown. (**G**) Fraction of genes associated with early-only, late-only, and static ZEB1 binding as well as the fraction of all genes significantly up (blue) and down (orange)-regulated after ZEB1 KD as measured at differentiation days 0 and 2.**DOI:** [http://dx.doi.org/10.7554/eLife.03346.013](10.7554/eLife.03346.013)

We next contrasted dynamically and statically ZEB1-bound regions in terms of their sequence properties, enrichment for other factors, as well as types of genes in their proximity. Early-only ZEB1-bound regions enriched for the non-adipogenic motifs RUNX1/2 (p \< 10^−5^) and TEAD1 (p \< 10^−5^), while late-only binding regions for the sequence motifs C/EBPα/β (p \< 10^−6^), NFIC (p ≤ 10^−3^), and PPARγ::RXR (p \< 10^−6^) ('Materials and methods'; [Figure 4C](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}), indicating that ZEB1 may in part relocate to adipogenic-specific regulatory regions after differentiation induction. Consistently, late-only ZEB1-bound regions showed strong C/EBPβ binding as well as high PPARγ and RXRα enrichments upon differentiation ([Figure 4B](#fig4){ref-type="fig"}). Moreover, these same regions also featured high DHS and POLII signals at days 2 and 4, respectively, suggesting that they become accessible and transcriptionally active during differentiation in contrast to early-only regions, which showed no to little DNase I hypersensitivity or POLII binding in 3T3-L1 pre-adipocytes ([Figure 4B](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). As these regions are largely already bound by C/EBPβ in pre-adipocytes ([Figure 4B](#fig4){ref-type="fig"}), it is possible that ZEB1 specifically relocates there upon differentiation induction to mediate gene activation. Functionally, late-only ZEB1 peaks were associated with genes annotated as important for fat cell differentiation, insulin response, and lipid storage among others ([Supplementary file 1G](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\], [Figure 4D](#fig4){ref-type="fig"}), a property distinct from early-only regions ([Supplementary file 1G](#SD1-data){ref-type="supplementary-material"}, [Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}).

Previously defined patterns of gene expression across 3T3-L1 differentiation ([@bib45]) further support this emerging, functional distinction of early and late ZEB1 enrichment. Specifically, we found that genes marked by early-only ZEB1 binding (≤ 10 kb distance, 'Materials and methods') were much more likely to have low expression in pre-adipocytes or to be repressed upon differentiation (clusters '1' and 'Low') ([Figure 4---figure supplement 1F](#fig4s1){ref-type="fig"}). On the other hand, late-only genes enriched for strong induction at either early of late time-points of adipogenesis (expression clusters '7' and '5') ([Figure 4---figure supplement 1F](#fig4s1){ref-type="fig"}). To further assess the functional impact of ZEB1 depletion on these late- vs. early-only bound genes, we integrated the expression data into our analyses ('Materials and methods'). The most notable observation was that a large fraction of late-only genes (here defined as genes that contain at least one late-only bound region but no early-only one) are down-regulated upon ZEB1 KD, with almost a quarter of them being significantly lower expressed at differentiation day 2 ([Figure 4E](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1G](#fig4s1){ref-type="fig"}), corresponding to an almost three-fold enrichment compared to statically bound genes (p ≤ 10^--12^, Fisher\'s exact test). Collectively, these results are consistent with the observation that an important fraction of genes that are induced during adipogenesis show increased proximal ZEB1 binding after addition of the differentiation cocktail.

We conclude that ZEB1 DNA binding is largely static during adipogenesis and given the strong overlap with DNase I hypersensitive sites may therefore contribute to establishing the regulatory landscape in pre- and mature adipocytes. Nevertheless, a subset of ZEB1 target sites is clearly dynamically bound. Genes that acquire ZEB1 binding after day 0 tend to be also bound by C/EBPβ, up-regulated after differentiation induction, particularly sensitive to alternation of nuclear ZEB1 levels and overall enriched for adipogenic functions. This suggests that ZEB1 may be involved in mediating the regulatory switch in primed pre-adipocytes toward the terminal differentiation program.

ZEB1: a core component of the adipogenic GRN {#s2-5}
--------------------------------------------

To gain a complete overview of all levels at which ZEB1 regulates adipogenesis, we specifically focused on the aGRN that we manually assembled and curated based on recent reviews as well as Wikipathways ([@bib58]; [@bib37]; [@bib66]). We displayed the network as well as fold-changes per gene after ZEB1 KD and information on ZEB1 and C/EBPβ binding using Pathvisio ([@bib81]) ([Figure 5A](#fig5){ref-type="fig"}). The vast majority of network members are directly targeted by ZEB1 and their expression significantly decreases upon ZEB1 KD (p = 2 × 10^−4^ based on permutation, 'Materials and methods'). The number of bound and regulated genes is significantly greater than expected by chance alone, suggesting that ZEB1 is a central component of the aGRN. As expected based on the co-localization of ZEB1 and C/EBPβ, the majority of ZEB1 targets are also targeted by C/EBPβ, suggesting that the two factors cooperate to promote adipogenesis.10.7554/eLife.03346.014Figure 5.ZEB1: a central component of the adipogenic regulatory network.(**A**) Effect of ZEB1 knockdown on the adipogenic gene regulatory network. The network was assembled on the 'Adipogenesis' Pathway scaffold in WikiPathways as well as reviews and most recent publications of novel adipogenic regulators ([@bib58]; [@bib37]; [@bib66]). ZEB1 and C/EBPβ-bound regions that are proximal (within 500 bp) to TSSs or genes in pre-adipocytes are highlighted. \*Significant (*padj* ≤ 0.01) expression changes after ZEB1 KD at day 0 of 3T3-L1 differentiation. Other candidate adipogenic regulators identified by our high throughput screen are listed. (**B**) Expression changes of adipogenic commitment genes after ZEB1 KD in 3T3-L1 pre-adipocytes as measured by RNA-seq. Displayed genes are either part of the pre-adipocyte expression signature derived by [@bib26] or of the list of pre-adipocyte commitment factors compiled by [@bib8]. *Lpl* and *Igfbp4* occur in both lists. Significant differences in expression (*padj* ≤ 0.01) are marked in orange (FC ≤ 0.67) and blue (FC ≥ 1.5). Black-grey squares depict ZEB1 binding to TSSs or gene bodies. (**C**) Effect of ZEB1 knockdown and overexpression on C3H10T1/2 adipogenesis as assessed by Oil Red O staining at day 7 and day 8, respectively after induction.**DOI:** [http://dx.doi.org/10.7554/eLife.03346.014](10.7554/eLife.03346.014)10.7554/eLife.03346.015Figure 5---figure supplement 1.ZEB1 regulates adipogenic commitment factors.(**A**) Effect of ZEB1 knockdown on the expression \[log2 (FC) mRNA\] of adipogenic (*Adipoq, Cebpa, Ebf1, Pparg2*) and EMT (*Snai1, Snai2, Twist1*) factors as measured by qPCR at day 8 after induction. (**B**) Effect of ZEB1 overexpression on the expression \[log2 (FC) mRNA\] of adipogenic (*Cebpa, Ebf1, Pparg2*), pre-adipogenic (*Zfp423, Zfp521*), and EMT (*Snai1, Twist1*) factors as measured by qPCR at day 0 after induction of differentiation. (**C**) Western Blot showing PPARγ induction upon ZEB1 overexpression (visualized using anti-HA antibody) in C3H10T1/2 cells using PCNA as a normalization control. R1-3 indicates biological replicates. Error bars depict the standard error of the mean. \*\*p ≤ 0.01 and 0.01 \< \*p ≤ 0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.03346.015](10.7554/eLife.03346.015)

One aspect emerging from the regulatory network display is that ZEB1 targets late onset master regulators such as C/EBPα and PPARγ, first wave regulators such as KLF4 and CREB, as well as early adipogenic commitment factors including ZFP423, TCF7L1, and EVI1 ([Figure 5A](#fig5){ref-type="fig"}). We thus performed a more systematic survey of the extent of ZEB1 binding to genes previously involved in adipogenic commitment, as defined by (1) a specific 3T3 pre-adipocyte expression signature ([@bib26]) and (2) pre-adipocyte factors found to be regulated at the expression level (recently compiled in [@bib8]). We found that the expression of about half (48%) of these genes significantly changes after ZEB1 KD in 3T3-L1 cells, with a striking majority (87%) of them being down-regulated. We note that this includes both transcriptional regulators such as the above-mentioned ZFP423, ligands such as WNT6 and membrane receptors such as PDGFRs ([Figure 5B](#fig5){ref-type="fig"}) and that the majority of their encoding loci are directly targeted by ZEB1 in un-induced pre-adipocytes ([Figure 5B](#fig5){ref-type="fig"}).

Given ZEB1\'s involvement in mediating the expression of early adipogenic commitment factors, we next tested whether ZEB1 also regulates adipogenesis in uncommitted precursors such as the C3H10T1/2 MSCs. C3H10T1/2 cells can be committed to the adipocyte lineage by activation of the TGFβ pathway by BMP2/4 and these cells subsequently differentiate into mature adipocytes by the addition of the same hormonal cocktail as used for 3T3-L1 differentiation ([@bib53]; [@bib75]). We found that upon shRNA-mediated reduction of ZEB1 levels, the differentiation of MSCs into adipocytes was significantly impaired despite addition of the commitment factor BMP-2 ([Figure 5C](#fig5){ref-type="fig"}). In addition, central adipogenic TFs and markers, including *Cebpa*, *Pparg2*, *Ebf1*, and *Adipoq*, were significantly down-regulated upon ZEB1 KD ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). We also investigated the effect of ZEB1 overexpression in C3H10T1/2 cells, and observed a slight increase in differentiation potential compared to control cells ([Figure 5C](#fig5){ref-type="fig"}). In addition, molecular analyses revealed a strong up-regulation of *Pparg2* and *Zfp423* mRNA levels ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}) as well as PPARγ protein levels ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}), providing further evidence as to the importance of ZEB1 in controlling the expression of this adipogenic master regulator. Collectively, these results indicate that ZEB1 is important for adipogenesis of both 3T3-L1 cells and MSCs.

ZEB1 is an important regulator of in vivo adipogenesis {#s2-6}
------------------------------------------------------

Our findings using mouse pre-adipocyte and mesenchymal cell cultures support an active, regulatory role for ZEB1 throughout adipogenesis and speak for a context- and dose-dependent function of this versatile transcriptional regulator. To assess whether these results also translate to an in vivo context, we next investigated the impact of altered ZEB1 levels onto in vivo adipogenesis.

Since *Zeb1* knockout mice are not viable ([@bib31]), we used a previously described method ([@bib36]; [@bib44]) to probe the effect of ZEB1 overexpression or KD on in vivo adipose stromal-vascular fraction (SVF) cell differentiation. Specifically, GFP-expressing, Matrigel-embedded murine SVF cells that were transduced with lentiviral particles containing either shRNAs or constitutive overexpression constructs for ZEB1 or negative controls were transplanted into the subcutaneous layer of the mouse neck. Mice with transplants were then subjected to a high fat diet for 6 weeks after which the Matrigel pads were analyzed for adipocyte number ([@bib44]) ([Figure 6A](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}).10.7554/eLife.03346.016Figure 6.ZEB1 is required for adipogenesis in vivo in mouse and its expression levels correlate with adipogenic indicators in humans.(**A** and **B**) Adipocyte differentiation in stromal vascular fraction (SVF) transplants from different donor mice (as indicated) fed a high-fat diet for 6 weeks ([@bib44]). (**A**) Fat sections from representative samples of ZEB1-overexpressing and control SVF transplants stained with Hematoxylin (blue) and Eosin (pink). (**B**) Fat cell content of the transplanted SVF cells containing ZEB1 and control overexpression or knockdown constructs. Error bars depict the standard error of the mean. \*p = 0.05, one-sided Wilcoxon-rank sum test. (**C**) *Zeb1* mRNA expression normalized to *36B4* in human subcutaneous SVF of obese subjects plotted against percent ex vivo differentiated adipocytes of human subcutaneous SVF, subject fat mass, and adiponectin levels. Spearman\'s ρ is indicated, \*\*p ≤ 0.01 and 0.01 \< \*p ≤ 0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.03346.016](10.7554/eLife.03346.016)10.7554/eLife.03346.017Figure 6---figure supplement 1.Analysis of the functional involvement of ZEB1 in mouse in vivo adipogenesis.(**A**) Hematoxylin (blue) and Eosin (pink)-stained fat sections from representative samples of mouse ZEB1 knockdown transplants as well as the corresponding control (scrambled siRNA). (**B**) Number of nuclei per section (average over three sections) from ZEB1 overexpression, KD, or control SVF transplants.**DOI:** [http://dx.doi.org/10.7554/eLife.03346.017](10.7554/eLife.03346.017)

Implanted SVF cells serving as controls produced a similar percentage of mature fat cells (∼12%), demonstrating high assay reproducibility. SVF cells overexpressing ZEB1 yielded a significantly (p = 0.05, Wilcoxon rank-sum test) higher number of mature fat cells compared to control ([Figure 6B](#fig6){ref-type="fig"}). Conversely, ZEB1 KD almost halved the formation of mature fat cells in the transplanted pad compared to the negative control ([Figure 6B](#fig6){ref-type="fig"}). Thus, ZEB1 is also highly important for adipogenesis in vivo. To assess whether the observed ZEB1 overexpression or KD effects could be linked to proliferation changes of adipocyte precursor cells, we quantified the nuclei from the implant sections ('Materials and methods'). We did not observe any change in proliferation in the ZEB1 KD and overexpression samples compared to the respective controls, although ZEB1 KD tended to yield more variable data ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). These results suggest that the observed effect of ZEB1 on adipogenesis does not involve major changes in the extent of cell proliferation capacity, although more in-depth molecular studies will be required to substantiate these findings.

Having demonstrated ZEB1\'s importance in mouse adipose biology, we asked whether its highly conserved ortholog would exert a similar function in humans. Interestingly, previous research linked sequence variation of the genomic locus in which *Zeb1* is located to body fat distribution and obesity ([@bib28]; [@bib29]), supporting a possible role for ZEB1 in these processes. To investigate this, we used subcutaneous fat biopsies from a previously sampled cohort of 62 obese patients (41 females and 21 males) with body mass indices (BMI) of 31--64 kg/m^2^ ([@bib44]; [@bib87]). Specifically, we determined *Zeb1* mRNA expression in the SVF from each patient\'s fat sample. We then correlated the resulting expression values to multiple adipose-relevant measures ([Supplementary file 1H](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\], 'Materials and methods'), including the ex vivo differentiation potential of human SVF from subcutaneous adipose tissue biopsies, as previously described ([@bib44]). Interestingly, we found strong positive correlations (Spearman\'s ρ ≥ 0.40, p ≤ 0.03) with adipocyte differentiation, total fat mass, as well as adiponectin levels ([Figure 6C](#fig6){ref-type="fig"} and [Supplementary file 1H](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\]). In contrast, it was previously reported that *Rorg* gene expression levels show an inverse correlation with adipocyte differentiation potential, and no significant correlation with either fat mass or adiponectin ([@bib44]) ([Supplementary file 1H](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\]). Thus, *Zeb1* SVF expression levels appear indicative of differentiation potential, fat mass, and adiponectin levels in humans, consistent with the positive effect of ZEB1 on adipogenesis observed in mice. Together, these results demonstrate the functional relevance of ZEB1 in the context of both mouse and human adipocyte biology.

Discussion {#s3}
==========

A TF overexpression screen identifies novel positive regulators of adipogenesis {#s3-1}
-------------------------------------------------------------------------------

A comprehensive understanding of the regulatory mechanisms mediating adipocyte differentiation has great fundamental and medical value. Significant efforts have therefore previously been undertaken to uncover adipogenic regulators. These range from classical phenotype- and 'guilt by association'-driven studies (reviewed in [@bib73]), over enrichment analyses in adipogenic compared to non-adipogenic clonal lines ([@bib26]; [@bib90]), to chromatin state-based inference of key regulators ([@bib11]; [@bib45]; [@bib85]). Of late, more large-scale studies have started to emerge in both mouse and human systems ([@bib83]; [@bib69]). Our study differs from these high-throughput screening approaches in that we set out to systematically identify novel transcriptional regulators of adipogenesis through an overexpression screen of TFs in 3T3-L1 pre-adipocytes. This was made possible due to the recent generation of a comprehensive library of mouse TF ORF clones ([@bib25]), which allowed us to explore the completeness of the so-far assembled aGRN ([Figure 5A](#fig5){ref-type="fig"}, \[[@bib73]\]).

We were able to identify several TFs having strong reproducible effects on fat cell differentiation. The majority of these have so far either never or only indirectly been linked to adipogenesis. For example, the only available information for the second ranking regulator ZFP30 is that it belongs to the family of KRAB zinc finger proteins, typically repressors with important roles in vertebrate development ([@bib80]). Other examples include MSX1 and ATOH8, which have been associated with differentiation processes in mesenchymal lineages but to our knowledge never with adipogenesis ([@bib9]; [@bib34]; [@bib56]). More generally, the identification of several novel adipogenic TFs suggests that, besides the well-characterized TF cascade including the C/EBP family of TFs and the canonical master regulator PPARγ, a substantial number of yet unconnected TFs also contribute to the adipogenic phenotype. This underscores the value of our screen, which provides a comprehensive resource that will accelerate the complete characterization of the core GRN underlying fat cell differentiation.

ZEB1 emerges as a central component of the aGRN {#s3-2}
-----------------------------------------------

The TF with the strongest effect on fat cell differentiation in our screen was ZEB1. This protein (also known as δEF1, TCF8, NIL2-a, BZP, AREB6, MEB1, ZFHX1a, and ZFHEP) is a highly conserved and versatile TF that was originally identified as a repressor of the lens-specific δ1-crystalline enhancer in chicken ([@bib17]). It has subsequently been shown to be involved in a broad range of regulatory processes, including EMT, tumor metastasis, development, and differentiation (reviewed in [@bib19]), providing a rationale as to why homozygous *Zeb1* null mice are not viable ([@bib31]). Similar to the majority of the other TFs identified in our screen, little is known about the involvement of ZEB1 in fat cell differentiation. One report linked a ZEB1 gain-of-function mutation to increased adiposity ([@bib41]), consistent with our findings; another found that female mice that are heterozygous for a targeted deletion of exon 1 of *Zeb1* show increased adiposity ([@bib63]), thus identifying ZEB1 as a repressor of adipogenesis. However, the latter study also reported that ZEB1 expression in parametrial fat increases as fat accumulates, in line with the results presented here. We therefore suspect that the phenotype observed in the studied ZEB1 haploinsufficient mice may not be related to adipocyte hyperplasia, but rather to hypertrophy, another well-established means of adipose tissue expansion. Thus, our findings consolidate and explain ZEB1\'s involvement in adipogenesis.

Indeed, (1) the large effects that reduction of ZEB1 levels has on the adipogenic phenotype and on the expression of both early (e.g. including ZFP423, TCF7L1 and EVI1) and late (e.g. PPARγ, C/EBPα, KLF15) members of the aGRN, (2) the fact that many of these TFs are also directly targeted by ZEB1, and (3) the fact that ZEB1 operates at the crossroads of several pathways underlying adipogenesis collectively indicate that this TF is an integral part of the molecular identity of pre-adipocytes. This is further supported by earlier observations revealing that *Zeb1* is expressed at high levels in adipose stem cells in vivo ([@bib40]), that it is significantly expressed higher in pre-adipocytes compared to adipocytes ([@bib35]), and that it is one of relatively few genes that is highly up-regulated during transition of mouse embryonic stem cells to adipocytes ([@bib6]). Interestingly, we found that many of the newly identified TFs such as ZFP30, MSX1, and ATOH8 are also highly expressed in pre-adipocytes. In addition, they are all direct targets of ZEB1 and their expression is affected by ZEB1 KD, suggesting that they may also have a role in early adipogenesis. The identification of several, putatively novel early adipogenic regulators likely reflects the nature of our experimental set-up, which employs early induction of TF overexpression before the cells undergo terminal differentiation. The ability to detect such early regulators is valuable, because the uncharted gene regulatory territory is especially confined to early processes rather than late ones for adipogenesis ([@bib26]).

To provide a mechanistic understanding of how ZEB1 mediates adipogenesis and to further characterize its regulatory mode of action, we assessed genome-wide gene expression differences after ZEB1 KD at days 0 and 2 of fat cell differentiation. In addition, we performed ZEB1 ChIP-seq at distinct time points during adipogenesis, providing a first glance into the dynamic DNA binding properties of ZEB1 in any biological system. We found that ZEB1 DNA binding is widespread, to an extent similar to that of other essential regulators such as C/EBPβ, PU.1, or MYC ([@bib30]; [@bib65]; [@bib48]), preferentially promoter-proximal and largely static, consistent with its relatively stable expression profile during terminal fat cell differentiation. In terms of sequence specificity, we found that ZEB1-bound regions were not only enriched for E-boxes (in particular 'CACCTG') as previously described, but also for a large number of DNA binding motifs of established adipogenic regulators, including C/EBPβ, AP1, and NFI factors ([@bib85]). Together with its strong overlap with DNase hypersensitive sites, these results suggest that ZEB1 contributes to establishing the regulatory landscape in pre- adipocytes as well as mature adipocytes.

Nevertheless, we found that a subset of ZEB1 target regions is dynamically bound. Genes that acquire ZEB1 binding upon differentiation induction tend to be co-bound by C/EBPβ, transcriptionally up-regulated, and enriched for adipogenic functions. These data suggest that ZEB1 may be involved in mediating the regulatory switch in primed pre-adipocytes toward the terminal differentiation program. Interestingly, a comparable mechanism has been uncovered in vascular smooth muscle cells, where ZEB1 has been shown to interact with SMAD3 and to synergistically activate the transcription of key differentiation genes ([@bib50]). In the context of adipocytes, we propose that ZEB1 forms a complex with C/EBPβ, as supported by our mass spectrometry data, and that these two TFs cooperate to control adipogenic gene expression. In contrast, we found that early-only bound regions were enriched for motifs of the osteogenic master regulator RUNX2, raising the possibility that ZEB1 may bind to osteogenic regulatory regions (likely in a repressive context), and may thus be involved in the bone-fat switch. This is consistent with ZEB1\'s previous implication in differentiation of various mesenchymal lineages, including osteogenesis, myogenesis, and chondrogenesis (reviewed in \[[@bib19]\]).

Importantly, murine ZEB1 shows strong conservation to its human ortholog and its gene was located within one of the top 16 regions of association in a recently performed meta-analysis of 32 body fat distribution genome-wide association studies ([@bib29]), consistent with an earlier report indicating a putative link between genomic variation in the *ZEB1* locus and obesity ([@bib28]). Our data from obese patients underscore this importance. Specifically, we found that *ZEB1* levels in the SVF correlate with differentiation potential, total fat mass, and circulating adiponectin levels. It is well accepted that adipocyte hyperplasia in obesity can lead to an increased fat cell number with smaller more insulin sensitive adipocytes ([@bib76]; [@bib57]). The positive correlation of *ZEB1* expression with adiponectin levels, which confers insulin sensitivity in a wide variety of tissues, points towards such a scenario. Our study therefore breaks new ground with respect to investigating the functional significance of this association.

Materials and methods {#s4}
=====================

Cell culture and differentiation {#s4-1}
--------------------------------

3T3-L1 mouse fibroblast cells and C3H10T1/2 mesenchymal stem cells, obtained from ATCC, were cultured in high-glucose Dulbecco\'s modified Eagle\'s medium (DMEM, Life Technologies, Carlsbad, CA) supplemented with 10% fetal calf serum (FCS, Bioconcept, Switzerland), and 1x penicillin/streptomycin solution (1x Pen/Strep, Life Technologies) in a 5% CO~2~ humidified atmosphere at 37°C and maintained at less than 80% confluence before passaging. Differentiation of 3T3-L1 cells was induced by exposing 2-day post-confluent cells (day 0) to DMEM containing 10% FCS supplemented with 1 µM dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine, and 167 nM insulin (Sigma, Saint-Louis, MO), a medium called MDI. Note that we did not add any rosiglitazone since the potent differentiation effect of this PPAR activator would have severely limited our ability to identify positive regulators of adipogenesis. After 2 days (day 2), cells were washed with Dulbecco\'s Phosphate-Buffered Saline 1x (PBS, Bioconcept, Switzerland) and were fed with DMEM containing 10% FCS and 167 nM insulin. 2 days later (day 4), the medium were changed to 10% FCS/DMEM. Full differentiation was usually achieved by day 6.

To identify the effect of ZEB1 overexpression or knockdown (KD) on differentiation of C3H10T1/2 cells into fat cells, 5 × 10^4^ cells were plated per well of six well plates. When the cells were 80% confluent, BMP-2 (50 ng/ml, Life Technologies) supplemented complete DMEM medium was added to the cells for commitment into pre-adipocytes. At confluence, day 0, adipocyte differentiation induction medium (MDI supplemented with 50 ng/ml BMP-2) was added to the cells. After 2 days the cells were washed once with 1x PBS and were fed with DMEM containing 10% FCS, 1x Pen/Strep solution containing 167 nM insulin and 50 ng/ml BMP-2. This was followed by the addition of 500 nM rosiglitazone containing complete media at day 4 to the cells. Rosiglitazone containing medium was changed after 2 days and then fat-containing cells were stained with Oil Red O at day 8.

TF cloning in overexpression lentiviral vector {#s4-2}
----------------------------------------------

The generation of our 750 fully sequence-verified mouse TF ORF clones via Gateway cloning is explained in Gubelmann et al. ([@bib25]). The 750 TF ORFs were subcloned from the pDONR221 entry clones into a Tet-On Gateway-compatible expression vector (IRES-PURO, 3 HA tags and Gateway sites were added to the original TRE_GOI_rtTA_hPGK vector \[[@bib5]\], by mixing 100 ng of TF entry clone with 100 ng of the expression vector and 0.5 µl of LR clonase II enzyme mix (Life Technologies). After incubating 18 hr at 25°C, this mix was transformed into competent STBL3 cells. Successfully subcloned TFs (734) were miniprepped using the NucleoSpin 96 Plasmid miniprep kit (Macherey--Nagel), typically yielding a concentration of approximately 150--300 ng/µl, from 2 ml overnight cultures in terrific broth II (MP Biomedicals, Santa Ana, CA). We note that the adipogenic regulators C/EBPα and C/EBPβ were not successfully cloned.

High-throughput lentiviral production (96 well plates) {#s4-3}
------------------------------------------------------

Lentivirus production was done using the TF ORF Tet-On Gateway-compactible expression vectors. Briefly, 293T packaging cells were seeded at 0.2 millions of cells/ml (100 µl per well) in low-antibiotic growth medium (DMEM, 10% iFBS (HyClone), 0.1x Pen/Strep) in a 96-well tissue culture plate (Corning, Corning, NY). The cells were incubated until they reached 70% confluence. In a 96-well polypropylene storage plate (Corning), 100 ng TF ORF Tet-On expression vector, 100 ng psPAX2 and 10 ng pMD2.G plasmids were mixed with OPTI-MEM (Life Technologies) to a total volume of 25 µl per well. At the same time, lipofectamine 2000 Transfection Reagent (Life technologies) was mixed with OPTI-MEM in an eppendorf tube (0.5 µl lipofectamine with 24.5 µl OPTI-MEM per well) and incubated for 5 min at room temperature. The transfection reagent mix was subsequently transferred to each well of the 96-well plasmid plate and the plate was incubated for 20 min at room temperature. Before transfection, the medium in the 96-well culture plate was changed with a fresh low-antibiotic growth medium, 100 µl per well, and the transfection mix (50 µl per well) was carefully transferred to the packaging cells. The cells were incubated for 18 hr in a 5% CO~2~ humidified atmosphere at 37°C. The medium was then replaced with 170 µl high-BSA growth medium (DMEM, 10% iFBS, 11 mg/ml microbiology-grade Bovine Serum Albumin (VWR Radnor, PA), 1x Pen/Strep). After 24 hr of incubation (37°C, 5% CO~2~), 150 µl per well was collected and stored at −20°C.

3T3-L1 lentiviral differentiation assay in a 384-well plate {#s4-4}
-----------------------------------------------------------

The differentiation assay was done in a collagen-coated 384-well black tissue culture plate for the overexpression screen. 3T3-L1 cells were seeded at a density of 20,000 cells per well (100 µl) and after 1 day, lentivirus was added to the medium (ratio 1:1 or 1:2 with the medium) with polybrene (8 µg/ml, Santa Cruz Biotechnology, Santa Cruz, CA). After 24 hr of incubation (37°C, 5% CO~2~), the medium was replaced with complete DMEM (DMEM, 10% FBS, 1% Pen/Strep) to remove viruses. When confluence was reached, the medium was changed with complete DMEM, 1 µl/ml Doxycycline (hyclate from Sigma) and cells were incubated for 72 hr (37°C, 5% CO~2~). Then, the cells were differentiated as described under 'Cell culture and differentiation', with addition of doxycycline in the medium until day 2. The cells were fixed and stained at day 7 of differentiation.

Fixation, staining, and image analysis {#s4-5}
--------------------------------------

The cells were washed with 100 µl 1x PBS per well and fixed by adding 1x PBS with 4% formaldehyde (Sigma). The cells were incubated at room temperature for 1 hr or overnight at 4°C. The fixation solution was then removed, cells washed once with 1x PBS and 100 µl of 1x PBS was added. Plates were then either stored at 4°C or stained immediately. Before staining, the cells were washed two times with water (100 µl). The staining of lipids with the lipophilic, fluorescent dye BODIPY, nuclei with Hoechst, and complete cells with SYTO60, the image acquisition (CellWorx, Applied Precision) and analyses were performed as described previously ([@bib44]). The percentage of differentiation (PDC) for each TF was obtained by dividing the number of cells having at least four lipid droplets by the total number of cells. Fold changes (FCs) were calculated by comparison to the differentiation percentages obtained with the original Tet-on expression vector (47.9% (average) of differentiation, [Supplementary file 1A](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\]). 307 TFs showing a FC \> 1 are displayed in [Figure 1B](#fig1){ref-type="fig"} and those with a FC ≥ 1.5 (i.e., a 50% increase in the fraction of mature adipocytes) in three technical replicates at a FWER of ≤ 0.05 (each replicate normalized to negative controls using normal transform and normal two-sided p-values corrected for multiple testing with Bonferroni\'s correction) were considered significant enhancers of adipogenesis, are referred to as 'candidates' in the manuscript, and are highlighted in red or orange in [Figure 1B](#fig1){ref-type="fig"} and in green in [Supplementary file 1A](#SD1-data){ref-type="supplementary-material"} ([@bib24]).

Analysis of candidates {#s4-6}
----------------------

We assessed which of the 26 candidates were endogenously transcribed in 3T3-L1 cells as well as human adipose stromal cells using publicly available data ([@bib49]; [@bib45]): mRNA levels (micro-array-based) as well as RNA POLII genome-wide binding (ChIP-seq). RNA POLII enrichment over gene bodies across all fat cell differentiation time points was used to determine whether genes were transcribed or not, based on a threshold adjusted by qPCR (10 sequence tags per 500 bp at the highest transcribed day; *data not shown*). We also used previously determined gene expression classes ([@bib49]) based on mRNA levels during differentiation of both human and mouse pre-adipocytes. The three qualitative transcription measures are listed in [Supplementary file 1A](#SD1-data){ref-type="supplementary-material"} ([@bib24]) for each candidate and summarized in [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}.

We used Expression Atlas (September 2013 version) to compare the expression of the candidates in adipogenesis (filters 'adipose' and 'adipose tissue') to their expression in other tissues. Nine and eight TFs, respectively, were significantly expressed higher and lower in adipose tissue compared to the average across all tissues (p = 0.05). This corresponds to a 1.5-fold enrichment of significantly higher expressed genes compared to random, an enrichment which is not significant (p = 0.1, 10,000 permutations).

Lentiviral production and stable cell lines {#s4-7}
-------------------------------------------

Viral particles containing Tet-on or shRNA expression plasmids were generated in 293T cells as described previously ([@bib4]), with slight modifications. Instead of five plates, one plate of 15 cm was transfected for each expression plasmid and the supernatant was harvested three times, every 8--12 hr. After the ultracentrifugation step (1 tube for each vector, 35 ml), the pellets were re-suspended in 35--45 µl of 1x PBS, centrifuged at maximum speed and stored at −80°C in 10 µl aliquots.

For stable and selected lines, 3T3-L1 cells at a density of 5 × 10^4^ cells were transduced with 10 µl viral particles in a six-well plate. After 12 hr, the medium was changed and puromycin (Life Technologies, 2 μg/ml) was added after 72 hr to select stably transduced cells. If the cell confluence reached 80%, the cells were split and transferred into larger dishes. After every 2 days, puromycin selection media was changed and the stably transduced cells were selected for 2 weeks before performing actual experiments.

For the Tet-On Gateway-compatible expression vector, the original vector was used as a negative control. For the KD, the lentiviral mammalian vector pLKO.1 containing specific shRNAs (three shRNAs per target were used, listed below) along with the control shRNA (empty pLKO.1 plasmid) were obtained from Sigma. Finally, the shRNA 2 ZEB1 was not used in the shRNA pool of ZEB1 as the robustness of the cells after treatment was low.

ShRNA: shRNA 1 PPARγ (TRCN0000001657), shRNA 2 PPARγ (TRCN0000001658), shRNA 3 PPARγ (TRCN0000001660), shRNA 1 ZEB1 (TRCN0000235850), shRNA 2 ZEB1 (TRCN0000235851), shRNA 3 ZEB1 (TRCN0000235853).

As the KDs were not stable for ZEB1 in these generated cell lines, we directly infected 50,000 3T3-L1 cells/well in six-well plates (three replicates per constructs). The medium was changed the following day, and when the cells reached confluence, we proceeded with the adipocyte differentiation protocol.

RNA isolation and quantitative PCR {#s4-8}
----------------------------------

Total RNA was isolated using a Qiagen RNAeasy plus mini kit according to the manufacturer\'s protocol by using either the RLT buffer lysis system or, for the RNA-seq samples, the TRIzol/Chlorophorm extraction procedure (Sigma, Saint-Louis, MO). The RNA concentration and quality was determined using a nanodrop (1.8 ≤ A260/A280 ≤ 2.2) and by visual inspection of separated bands on agarose gels. 2 µg of total RNA was used for single strand cDNA synthesis using the SuperScript VILO cDNA Synthesis Kit (Life Technologies). Then, cDNA was diluted 1:100 using nuclease free water and 1.5 µl was used for each qPCR reaction. Quantitative real-time PCR was performed in 384-well plates with three technical replicates on the ABI-7900HT Real-Time PCR System (Applied Biosystems) using the Power SYBR Green Master Mix (Applied Biosystems) using standard procedures. A Hamilton Liquid Handling Robotic System was used to assemble the 384-well plates. The qPCR primers were designed with in-house developed GETPrime software ([@bib23]) or taken from previous publications ([Supplementary file 1I](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\]). They were checked for linearity and single product amplification.

In vivo differentiation {#s4-9}
-----------------------

The in vivo experiments were performed as described in [@bib44] by using the shRNAs listed above and the ZEB1 as well as PPARγ (positive control) overexpression clones. In short: fat tissue was dissected, minced and incubated in collagenase type II for 1 hr at 37°C. Approximately 106 cells were treated with virus and resuspended in 100 μl of Matrigel (BD Biosciences, San Jose, CA) before injection subcutaneously into a skin fold of the neck. After 6 weeks, Matrigel pads were excised. From each pad pictures of three full sections were taken and adipocyte numbers as well as the number of nuclei were determined automatically using the Cell Profiler Software. To overcome the doxycycline effect of a Tet-on inducible lentiviral vector, the TF ORFs were subcloned from the pDONR221 entry clones into the pLenti6/UbC/V5-DEST expression vector (Life Technologies, Carlsbad, CA). As negative controls, the original vector and the shEMPTY (Sigma) were used. All experiments were performed in three replicates and the significance of the observed changes was estimated using a one-sided Wilcoxon rank-sum test.

Ex vivo differentiation of human SVF {#s4-10}
------------------------------------

Differentiation of the pre-adipocytes was induced as described previously ([@bib44]). RNA were extracted after day 8 of differentiation and analyzed by qPCR, as explained above. mRNA expression was normalized to *36B4*. For expression of *Zeb1*, TaqMan gene expression assays (Ambion Life Technologies, Carlsbad, CA) were used according to the manufacturer\'s protocol. Differentiated cells were co-stained with adiponectin to verify differentiation.

RNA-seq {#s4-11}
-------

After isolation of RNA, as described in the section 'RNA isolation and quantitative PCR', the Illumina Truseq RNA Sample Preparation kit v2 protocol (Illumina, San Diego, CA) was followed using 500 ng of RNA per sample as starting material. Half of the ligated reaction volume was used for PCR (14 cycles) and the other half was kept at −80°C as a backup. Libraries were checked for quality and quantified using the Bioanalyzer 2100 (Agilent, Santa Clara, CA), before being sequenced in barcoded pools of 16 samples on the Illumina Hiseq 2500 instrument (100 base paired-end sequencing, 4 lanes; Genomics Sequencing Facility, Nestle, Lausanne).

RNA-seq analysis {#s4-12}
----------------

Sequenced tags were aligned to Ensembl 70 gene annotation of the NCBI38/mm10 genome using Bowtie 1.0.0 and the parameters '-a \--best \--strata -S -m 100 \--chunkmbs 256 -p 8'. Expression levels per transcript and gene were estimated using mmseq-1.0.2 ([@bib79]) with default parameters. Quantile normalized expression estimates were transformed into pseudo-counts by un-logging, un-standardising and multiplying with gene length. Expression differences between the samples were quantified with DESeq ([@bib1]), FC ≥ 1.5 and *padj* ≤ 0.01. Estimated FCs were validated by using qPCR-measured FCs at days 0 and 2, revealing significant correlations with Pearson\'s r \> 0.95 and p = 2 × 10^−4^ and p = 3 × 10^−5^, respectively.

Chromatin Immunoprecipitation {#s4-13}
-----------------------------

3T3-L1 stably selected cells were collected at days −2, 0, 2 and 4 for ZEB1. The cells were fixed as described previously ([@bib55]) and stored at −80°C. Ten million cells were used for each immunoprecipitation (IP). The ChIP experiment was performed as described previously in [@bib55], under 'Chromatin Immunoprecipitation of SMRT'. A ZEB1 antibody (Santa Cruz, sc-25388, 10 μg per IP) and a rabbit isotype control IgG (Santa Cruz Biotechnology, Santa Cruz, CA, sc-8994, 10 μg per IP) was used for each time point. The DNA was stored at −20°C until verification of ChIP enrichment by qPCR and ChIP-seq library preparation.

For the ChIP of ZEB1-HA and C/EBPβ, the chromatin samples were incubated overnight at 4°C with an anti-HA antibody (Abcam, UK, ab9110, 5 μg per IP), an anti-C/EBPβ antibody (Santa Cruz, sc-150, 10 µg per IP) respectively, or a rabbit control IgG (Santa Cruz, SC-8994) coupled to magnetic beads (sheep anti-rabbit IgG, Life Technologies, Carlsbad, CA Dynabeads), as described previously ([@bib38]) with few modifications. 50 μl of antibody-coupled beads were added to each 1 ml chromatin material instead of 100 μl. After incubation, we washed the beads five times with a LiCl wash buffer (100 mM Tris at pH 7.5, 500 mM LiCl, 1% NP-40, 1% sodium deoxycholate), mixed for 10 min at 4°C and removed remaining ions with a single wash with 1 ml of TE (10 mM Tris--HCl at pH 7.5, 0.1 mM Na2EDTA) at 4°C for 1 min mix. The beads were then resuspended in 200 μl IP Elution Buffer (1% SDS/0.1 M NaHCO3), incubated in a 65°C shaker for 1 hr and placed on the magnet to recover the supernatant. The supernatant was incubated at 65°C overnight to complete the reversal of the formaldehyde cross-links. The next day, DNA was purified from the reverse-crosslinked chromatin by proteinase and RNase digestion followed by purification using Qiagen DNA purification columns.

ChIP-seq {#s4-14}
--------

Multiplex libraries were prepared using barcoded adapters for each sample following the protocol described in [@bib54] with slight modifications. In brief, ChIP-DNA fragments were end-repaired using an End-IT DNA end repair kit (Epicentre Technologies) followed by the addition of an A-base and ligation of bar-coded adapters. After the ligation incubation, the DNA was cleaned up using Agencourt AMPure XP Beads (Beckman Coulter, Fullerton, CA) and eluted in 12 µl. These purified, ligated DNA fragments were separated on a 2% agarose gel to select 200--500 bp-sized DNA fragments and DNA was subsequently isolated from gel slices using a Qiagen gel extraction kit. The gel-extracted DNA was then amplified for 17 cycles by PCR using high fidelity Phusion hot start polymerase (NEB, Ipswich, CA). The concentration and quality of purified, amplified DNA were estimated using respectively a Qubit dsDNA high sensitivity kit (Life Technologies) and a high sensitivity DNA assay Bioanalyzer 2100 (Agilent). After quality confirmation, the DNA libraries were sequenced on an Illumina High Seq 2500 (Genomics Sequencing Facility, Nestle, Lausanne; Genomic Technologies Facility, UNIL, Lausanne). Pass-filtered reads from the Illumina analysis pipeline were used for further analysis.

Absolute quantification of ZEB1 {#s4-15}
-------------------------------

### Peptide selection {#s4-15-1}

For ZEB1 quantification, the following three proteotypic peptides were selected: VAVDGNVIR, AYYALNAQPSTEELSK and IADSVNLPLDGVK. Nuclear extracts (NE) at differentiation time points: day 0, 2 hr (2 hrs), day 2 and day 4 were analyzed as three biological and three technical replicates (*n* = 3). A total amount of 200 μg of NE was used for SDS-PAGE analysis followed by in gel trypsin digestion of the target protein. Heavy labelled (lysine, K) and accurately quantified synthetic peptide standards (JPT SpikeTides, JPT Peptide Technologies GmbH, Germany) were added to the digested NE at a final concentration of 5 fmol/μl. Relative levels of RXRα protein were monitored by SRM along with ZEB1 protein as a quality control for all analyzed NE. The following three proteotypic peptides for RXRα: GLSNPAEVEALR, ILEAELAVEPK, and VLTELVSK, were selected and monitored by SRM as described previously ([@bib68]).

### Liquid chromatography {#s4-15-2}

Dried NE peptides were resuspended in 30 μl LC-MS/MS loading solvent (5% acetonitrile, 0.1% formic acid). Following resuspension, samples were allowed to settle for 1 hr to increase overall peptide solubility before SRM analysis. Typically, 5 μl of sample was loaded and captured on a homemade capillary pre-column (C18; 3 μm, 200 Å; 2 cm × 250 μm) before analytical LC separation (nanoACQUITY UPLC, Waters). Samples were separated using a 80-min biphasic gradient starting from 100% solvent A (2% acetonitrile, 0.1% formic acid) to 90% solvent B (100% acetonitrile, 0.1% formic acid) on a Nikkyo (Nikkyo Technology, Japan) nanocolumn (C18; 3 μm, 100 Å; 15-cm length and 100-μm inner diameter; flow of 0.5 μl/min). The gradient was followed by a wash for 8 min at 90% solvent B and column re-equilibration for 12 min at 100% solvent A.

### Selected reaction monitoring (SRM) of ZEB1 peptides {#s4-15-3}

All samples were analyzed on a TSQ-Vantage triple quadrupole mass spectrometer (Thermo Fisher Scientific, Waltham, MA). A 0.7-FWHM-resolution window for both Q1 and Q3 was set for parent- and product-ion isolation. Fragmentation of parent ions were performed in Q2 at 1.5 mtorr, using collision energies calculated with the Pinpoint software (v.1.3). Parent-ion selection was set for fully digested peptides of the doubly charged ion for target peptides. Peptide fragment transitions and collision energies were established using the heavy labelled synthetic reference peptides (JPT SpikeTides). Generally, singly charged peptide fragment ions ranging from y~3~ to y~*n*--1~ were monitored. A parent-ion retention-time target window of 2 min was selected for all proteins monitored during a scheduled SRM ru*n.* A total of 79 transitions were monitored during a single LC-SRM run, using a cycle time of 0.5 s and a minimum dwell time of 10 ms. All data analyses were carried out using Pinpoint software (v.1.3). Peptide identification and peak-area integration of all targeted peptides as well as their transitions were manually verified in Pinpoint.

While absolute ZEB1 levels fluctuated about two-fold between biological replicates likely due to technical variations in the levels of the targeted peptides, the overall trend was consistent between biological replicates ([Figure 2A](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}).

ZEB1 immunoprecipitation and mass spectrometry {#s4-16}
----------------------------------------------

For IP of ZEB1 protein complexes, 3T3-L1 cells stably overexpressing ZEB1 and control vectors were grown in 150-mm plates and ZEB1 expression was induced at day −2 (the time of cell confluence) using doxycycline as described before. At day 0 of differentiation, the cells were washed with 1x PBS and dissociated using trypsin-EDTA solution (Life Technologies). The dissociated cells were collected in 15-ml falcon and centrifuged at 250 × g to pellet the cells. The cell pellet was washed once with 1x PBS containing 1 mm PMSF (phenylmethylsulfonyl fluoride) protease inhibitor and stored at −80**°**C. Before lysing the cells for IP, recombinant protein-A sepharose beads (Life Technologies) were prepared by washing with IP buffer (20 mM Tris-Cl, pH. 7.4, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EDTA, 1 mM DTT) supplemented with protease and phosphatase inhibitors (Roche). The anti-rabbit HA tag antibody (Abcam, UK) was conjugated with the protein-A sepharose beads by incubating antibody with the beads overnight at 4**°**C at rotation. The cells were then lysed in 1 ml IP buffer by douncing 20-25 times using 1 ml syringe. Lysates were cleared by centrifuging at maximum speed in a tabletop refrigerated centrifuge for 10 min. The tagged complexes were pulled down using 50 μl HA-antibody tagged beads for 4 hr at 4**°**C at rotation. The beads were then washed 5 times using IP buffer and the bound protein complexes were eluted by heating the beads in 60 μl 2x Laemmli sample buffer. To resolve the proteins present in pull down complexes, a 12% SDS-PAGE gel was used.

Entire lanes of SDS-PAGE gels were then sliced into pieces. Samples were first washed twice for 20 min in 50% ethanol and 50 mM ammonium bicarbonate (AB). Gel slices were dried down by vacuum centrifugation. All samples were reduced/alkylated using dithioerythritol and iodoacetamide. Gel pieces were dried again and re-hydrated using trypsin solution (12.5 ng/µl in 50 mM AB and 10 mM CaCl2). Trypsin digestion was performed overnight and resulting peptides were extracted twice for 20 min in 70% ethanol and 5% Formic Acid (FA). Samples were dried down and re-suspended in 2% acetonitrile and 0.1% FA for LC-MS/MS injections. One-dimensional liquid chromatography separation was performed on a Dionex Ultimate 3000 RSLC nano UPLC system (Dionex, Sunnyvale, CA) on-line connected with an Orbitrap Q Exactive Mass-Spectrometer (Thermo Fischer Scientific). A self-made capillary pre-column (Magic AQ C18; 3 μm-200 Å; 2 cm × 100 μm ID) was used for sample trapping and cleaning. Analytical separation was then performed using a C18 capillary column (Nikkyo Technos Co, Japan; Magic AQ C18; 3μm-100 Å; 15 cm × 75 μm ID) at 250 nl/min. Separation of peptides was carried over an 85 min biphasic gradient. Mass spectrometric measurements were performed using a data-dependent top 20 method, with the full-MS scans acquired at 70 K resolution (at m/z 200) and MS/MS scans acquired at 17.5K resolution (at m/z 200). A database search was performed using Mascot 2.3 (Matrix Science) and SEQUEST in Proteome Discoverer v.1.3 against a mouse database (UniProt release 2013_09). All searches were performed with trypsin cleavage specificity, up to two missed cleavages were allowed and ion mass tolerance of 10 ppm for the precursor and 0.05 Da for the fragments. Carbamidomethylation was set as a fixed modification, whereas oxidation (M), acetylation (Protein N-term), phosphorylation (STY) were considered as variable modifications. Data were further processed and inspected in the Scaffold 4 software (Proteome Software, Portland, OR).

ChIP-seq analysis {#s4-17}
-----------------

Sequenced ChIP tags were aligned to the NCBI38/mm10 genome with Bowtie2 ([@bib42]) and the parameters '\--very-sensitive -M 10 -p 8'. Duplicates were removed, as well as the reads with a mapping quality under 10. Regions showing significant ChIP enrichment (peaks) with CCAT 3.0 ([@bib89]) ('fragmentSize 200 slidingWinSize 100 movingStep 50 isStrandSensitiveMode 1 minCount 13 minScore 5 bootstrapPass 80', FDR 0.1) or Homer ([@bib30]) ('-F 3 -L 4 -localSize 5000 -C 4 -fragLength 200 -minDist 500 -center') using anti-HA (in Zfp277-HA overexpressing cells, where Zfp277-HA serves as negative control as it is not imported into the nucleus, *data not shown*) as control were merged into common ZEB1-bound regions. This resulted in a total of 43,405 ZEB1 bound regions (10,708 day −2, 27,854 day 0, 18,145 day 2, 22,249 day 4) and 19,055 ZEB1-HA bound regions (day 0). Read counts contained in the genomic intervals defined by day 0 and merged ZEB1 binding, respectively, were correlated and the Spearman\'s ρ used to generate hierarchically clustered heatmaps ([Figure 3---figure supplement 1B--C](#fig3s1){ref-type="fig"} and [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). As biological replicates were only available for days −2 and 0, we compared the read counts contained in the genomic intervals defined by merged ZEB1 binding at early time points (two replicates day −2 and high enrichment replicate day 0 treated as replicates) to those at late time points (single replicate day 2 and single replicate day 4 treated as replicates) using DESeq 1.2.3. We obtained 803 regions showing significantly (*padj* ≤ 0.1, FC ≥ 2) higher ZEB1 ChIP-seq read counts at days 2 and 4 vs. days −2 and 0 (*late-only* ZEB1 binding) and 552 regions showing significantly higher ZEB1 ChIP-seq read counts at days −2 and 0 vs. days 2 and 4 (*early-only* ZEB1 binding). Genes overlapping at least one late-only bound region (gene body +500 bp upstream of TSS) and no early-only bound region were considered 'late-only genes'; conversely, genes overlapping at least one early-only bound region (gene body +500 bp upstream of TSS) were considered 'early-only genes'. Genes overlapping only statically ZEB1-bound regions were considered 'static-only genes'.

Motif discovery {#s4-18}
---------------

Motif discovery was performed with HOMER\'s findMotifsGenome ([@bib30]) ("-size 100 -len 6,8,10,12,14 -local") on all ZEB1-bound regions at day 0 (summary results are displayed in [Figure 3D](#fig3){ref-type="fig"} and complete results listed in [Supplementary file 1E](#SD1-data){ref-type="supplementary-material"} \[[@bib24]\]) and with MEME 4.9.1 ([@bib3]) ('-nmotifs 10 -minsites 10 -minw 4 -maxw 20 -revcomp -maxsize 60,000 -dna') using 50 bp centered on the summits of the most highest-scoring 1000 ZEB1-bound regions at day 0 (the top enriched motif is displayed in [Figure 3C](#fig3){ref-type="fig"}). Motif matching to known motif databases was performed using TOMTOM 4.9.1 ([@bib3]) and 'All vertebrates' database. Motif scanning of bound regions (100 bp centered around the summit of ZEB1-bound regions at day 0 as well as randomly shifted regions for background comparison) was performed with the PWMs available through [@bib86] and Jaspar ([@bib7a]) for ZEB1, CEBPB, AP1, NFIC and SMAD3 using the package Biostrings 2.30.0 at a cutoff of 85%. Percentage of peaks showing at least one and at least two PWM matches are displayed in [Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}. ZEB1 PWM matches in an 800 bp region centered on ZEB1 peak summits (at day 0) were displayed as a motif density plot in [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}. Differential motif discovery contrasted early-only and late-only ZEB1-bound regions with static (*padj* \> 0.1, FC \< 2) ones. Early-only ZEB1 binding enriched for RUNX (MEME E = 7 × 10^−29^, matching RUNX2/MA0511.1, TOMTOM p = 2 × 10^−6^ and RUNX1/MA0002.2, TOMTOM p = 7 × 10^−6^) and TEAD1 (MEME E = 2 × 10^−7^, matching TEAD1/MA0090.1, TOMTOM p = 5 × 10^−6^) motifs, while late-only binding enriched for C/EBP (MEME E = 9 × 10^−179^, matching C/EBPα /MA0102.3, TOMTOM p = 1 × 10^−12^ and C/EBPβ/MA0466.1, TOMTOM p = 2 × 10^−7^), NFI (MEME E = 4 × 10^−12^, matching NFIC/MA0161.1, TOMTOM p = 9 × 10^−5^ and TLX::NFIC/MA0119.1, TOMTOM p = 1 × 10^−3^) and PPARG::RXR (MEME E = 3 × 10^−6^, matching PPARG::RXR/MA0065.2, TOMTOM p = 4 × 10^−7^) motifs, as displayed in [Figure 4C](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}.

Annotation and Gene Ontology enrichment {#s4-19}
---------------------------------------

ZEB1 bound regions and regulated genes were annotated using Ensembl 70. Peaks were assigned (in this order) to either TSS (± 500 bp of annotated TSS), exonic regions (but not TSS), intronic regions (but not TSS or exons), gene proximity (10 kb distance to a gene, but not TSS or gene), or gene-distal regions (none of the above) and the fraction belonging to these categories displayed as pie charts in [Figure 3B](#fig3){ref-type="fig"}. For comparison, we performed the same analysis for randomly shifted ZEB1, C/EBPβ (day 0), and POLII (day 0) bound regions ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}). Additionally, we used HOMER\'s annotatePeaks with default options to assign each peak to its closest gene and report the p-values obtained using the hypergeometric test in the manuscript as indicative of a significant association of ZEB1 binding with promoters, CpG islands and exons. Complete results are included in [Supplementary file 1D](#SD1-data){ref-type="supplementary-material"} ([@bib24]). GO term enrichment analysis of ZEB1-regulated genes was performed with GeneGO MetaCore (<https://portal.genego.com/>), representative summaries are displayed in [Figure 2C](#fig2){ref-type="fig"} and complete results included in [Supplementary file 1C](#SD1-data){ref-type="supplementary-material"}. GO term enrichment analysis on ZEB1-bound regions was performed with GREAT using default parameters ([@bib43]), contrasting late-only and early-only regions with static ones. Selected results are displayed in [Figure 4D](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"} and complete ones are included in [Supplementary file 1G](#SD1-data){ref-type="supplementary-material"} ([@bib24]).

Publicly available data {#s4-20}
-----------------------

We used the following publicly available data: (1) in 3T3-L1 cells: microarray-based gene expression, ChIP-seq using antibodies against JUNB, FOSL, CJUN, ATF7, ATF2, C/EBPβ, PPARγ, POLII, H3K9AC, RXRα, DNAse-seq ([@bib49]; [@bib71]; [@bib65]; [@bib55]; [@bib67]); (2) pre-adipocyte vs. adipocyte data and meta-analysis of mouse tissue expression data available through Array Express (September 2013) ([@bib62]); (3) Human ENCODE HepG2 and lymphoblastoid cell lines (LCLs): ChIP-seq with antibodies against C/EBPβ, FOSL, JUN and ZEB1 ([@bib12]). All ChIP-seq and DNase-seq data were reanalyzed analogous to the in-house generated data. The human data was aligned to the GRCh37 (hg19) genome. Overlaps between regions bound by ZEB1 (or randomly shifted ZEB1) and C/EBPβ at day 0 as well as AP1 factors (JUNB, FOSL, CJUN, ATF7 and ATF2) at 4 hr (day 0) are displayed as Venn diagrams using the R package VennDiagrams 1.6.5 in [Figure 3E](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1G](#fig3s1){ref-type="fig"}.

Heatmaps and genomic loci displays {#s4-21}
----------------------------------

Read counts were divided by normalization factors estimated using DESeq2 and shifted ZEB1 peaks as genomic intervals and extended to 200 bp each. Counts were then summed across 400 windows of 5 bp each (total 2 kb) centered around ZEB1 peak summits and log2 transformed. These transformed values (referred to as 'norm ChIP' in [Figures 3F and 4B](#fig3 fig4){ref-type="fig"}, [Figure 3---figure supplement 1H](#fig3s1){ref-type="fig"}, and [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}) were displayed as heatmaps using the R package pheatmap 0.7.7. We note that only a subset (top, mid and bottom 4000 peaks sorted by mean ZEB1 day 0 ChIP enrichment) is displayed in [Figure 3---figure supplement 1H](#fig3s1){ref-type="fig"} and only the two AP1 factors showing the highest colocalization (data not shown) with ZEB1---ATF2 and ATF7---are displayed in [Figure 3F](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1H](#fig3s1){ref-type="fig"}. Similarly, counts for the human ChIP-seq datasets were normalized to the library size, extended to 200 bp and log2 transformed. Mean values in a 8 kb region centered on ZEB1 peak summits in lymphoblastoid cell lines (LCLs) were then plotted in [Figure 3---figure supplement 1I](#fig3s1){ref-type="fig"}. Genomic loci plots were visualized in the UCSC Genome Browser based on bedGraph files obtained using HOMER\'s makeUCSCfile and the parameters '-o auto -res 1 -fsize 5e7\'. The scale used for each individual track is displayed in [Figures 3A and 4A](#fig3 fig4){ref-type="fig"}, [Figure 3---figure supplement 2E](#fig3s2){ref-type="fig"} and [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}.

Adipogenic gene regulatory network {#s4-22}
----------------------------------

We used Wikipathways, as well as recent reviews to manually compile an adipogenic transcriptional regulatory network ([@bib37]; [@bib58]; [@bib66]) and displayed it using Pathvisio ([@bib81]). We then superimposed the expression information (log2 FCs and multiple-testing corrected p-values after ZEB1 KD at day 0) as well as ZEB1 and C/EBPβ binding information (at day 0: overlapping TSS or overlapping the gene) on the network in [Figure 5A](#fig5){ref-type="fig"}.

Bioethics {#s4-23}
---------

All mouse experiments were conducted in strict accordance with Swiss law and all experiments were approved by the ethics commission of the state veterinary office (60/2012, 43/2011). The work on obese subjects was approved by the ethics committee at the University Hospital of Heidelberg and is conforming to the ethical guidelines of the 2000 Helsinki declaration. All participants provided witnessed written informed consent prior to entering the study (S-365/2007). The trial was registered as NCT00773565.

Data access {#s4-24}
-----------

ChIP-seq data are available in the ArrayExpress database ([www.ebi.ac.uk/arrayexpress](http://www.ebi.ac.uk/arrayexpress)) under accession number E-MTAB-2537. RNA-seq data are available in the ArrayExpress database under accession number E-MTAB-2538. Results of the TF overexpression screen, processed RNA-seq data, mass spectrometry results and the clinical data ([Supplementary file 1A](#SD1-data){ref-type="supplementary-material"}, [Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}, [Supplementary file 1F](#SD1-data){ref-type="supplementary-material"} and [Supplementary file 1H](#SD1-data){ref-type="supplementary-material"}) have additionally been deposited in the Dryad data repository under [doi: 10.5061/dryad.j966f](http://dx.doi.org/10.5061/dryad.j966f) (see [@bib24]).
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[@bib24]. (**A**) Transcription factor screen. Percentage differentiated cells in response to TF overexpression. Raw values, fold-changes with respect to control, p-values and associated annotations are included for all TFs showing positive effects on adipogenesis. TFs significantly enhancing differentiation are highlighted in green (FC ≥ 1.5, Bonferroni α = 0.05). (**B**) mRNA levels upon ZEB1 knockdown. Estimated expression levels in all RNA-seq replicates (shZEB1 and shEmpty at days 0 and 2), fold-changes and p-values as well as information ZEB1 and C/EBPβ binding at gene TSS, gene bodies or in gene proximity. (**C**) Pathway Enrichments. Pathways enriched in genes significantly de-regulated upon ZEB1 knockdown at days 0 and 2. (**D**) Gene Ontology Enrichments Genomic features enriched at ZEB1-bound locations. (**E**) Motifs in ZEB1 bound regions. Motifs enriched in 100 bp centered on ZEB1 peak summits. (**F**) Mass Spectrometry results. List of proteins detected by at least one peptide in any of the two performed ZEB1 immunoprecipitation experiments. (**G**) GREAT Gene Ontology enrichments. GO Terms enriched in genes proximal to late-only and early-only ZEB1-bound regions. (**H**) Clinical data: Correlation of *Zeb1* and *Rorg* mRNA levels in human obese subjects with a range of adipogenesis-relevant measures. Raw values are included for the significant correlations discussed in the manuscript. (**I**) qPCR primers. List of primers used for gene expression analyses and ChIP-qPCR.

**DOI:** [http://dx.doi.org/10.7554/eLife.03346.018](10.7554/eLife.03346.018)
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "Identification of ZEB1 as a central component of the adipogenic gene regulatory network" for consideration at *eLife*. Your article has been favorably evaluated by Fiona Watt (Senior editor) and 3 reviewers, one of whom is a member of our Board of Reviewing Editors.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

The reviewers were in agreement that the work was exciting and potentially of interest to the readers of *eLife*. However, several major issues were identified that need to be addressed in order to strengthen the conclusions drawn. These issues are summarized below:

1\) Clarification regarding the screening system. Under standard conditions, close to all 3T3-L1 cells typically differentiate. That suggests that the setup used for the transcription factor screen somehow affects the differentiation capacity of the control cells, which allows one to identify factors that result in an increase in the differentiation capacity. This is supported by the relatively low degree of differentiation of the control cells in [Figure 1C](#fig1){ref-type="fig"} compared to control cells in [Figure 1D](#fig1){ref-type="fig"}. This should be clarified in the manuscript. Microscopic pictures of the differentiation capacity of control cells would be valuable for evaluation of the degree of differentiation. Also, based on the Western blotting in S1c, it isn\'t clear what is being overexpressed. Why are there so many HA-tagged products of such varying sizes?

2\) Effect of ZEB1 knockdown on ZEB1 promoter occupancy. The ChIP-seq for Zeb1 should have a knockdown control. There are a large number of weak peaks, most of which seem not to have the ZEB1 motif. How many of these peaks are still present in the absence of ZEB1?

3\) Relationship of ZEB1 and C/EBPb. The authors convincingly show that ZEB1 binds to many chromatin regions together with C/EBPβ and this factor also associates with ZEB1 in a co-IP experiment indicating that these factors cooperate on chromatin. This conclusion would be strengthened if it could be demonstrated that C/EBPβ binding to chromatin is affected by ZEB1 knockdown and vice versa.

4\) Better correlation between gene expression and promoter occupancy. The correlation between ChIP-seq data and gene expression profiles is well documented ([Figure 4](#fig4){ref-type="fig"} and supplemental information). However, it would be informative if the RNA-seq data upon ZEB1 knock down were included here to make it clear whether genes associated with early, late, or static ZEB1 binding are in fact affected by ZEB1 knock down. The data is already used in [Figure 2](#fig2){ref-type="fig"}, so it should be straightforward to analyze the effect of knock down on the expression of putative direct ZEB1 target genes identified by ChIP-seq.

5\) Additional data for the in vivo studies. For the in vivo differentiation of implanted precursor cells, it would be relevant to know whether ZEB1 knockdown affects proliferation of precursor cells, their commitment or just their maturation to adipocytes. Also, data on gene expression would be informative.

6\) Clarification of the human data. The human data in Figure 7 is somewhat at odds with prior results. Is adiponectin positively correlated with body weight in these samples? It looks like it might be, which is not generally how those two variables interact.

7\) Claims regarding commitment are premature. A weak point in the manuscript is the data on the importance of ZEB1 for commitment of MSCs to the adipocyte lineage. Although the authors provide evidence that ZEB1 is required for terminal differentiation of MSCs (i.e. C3H10T1/2 cells), it is not clear if this is because ZEB1 is required for the commitment step. The analysis of expression of Zfp423 and Zfp521 upon ZEB1 knock down is not convincing in itself. If the authors want to claim that ZEB1 also regulates commitment, this should be more thoroughly evaluated experimentally. Note, the editor believes that this question is better suited for a future manuscript and strongly suggests that the authors simply soften their conclusions regarding a role in commitment in the present paper. Alternatively, if the authors wish to make this claim, additional studies would be required. Some of the questions that could be addressed include: (1) can over expression of ZEB1 substitute for BMP-2/4 signaling to commit C3H10T1/2 cells to the adipocyte lineage?; (2) does overexpression of ZEB1 decrease the potential of C3H10T1/2 cells to develop into other cell lineages?; (3) is transient overexpression or knock down during commitment enough to enhance or decrease, respectively, differentiation of C3H10T1/2 cells?; or (4) is overexpression or knock down only during terminal differentiation of C3H10T1/2 enough to enhance or inhibit differentiation, respectively?

10.7554/eLife.03346.020

Author response

*1) Clarification regarding the screening system. Under standard conditions, close to all 3T3-L1 cells typically differentiate. That suggests that the setup used for the transcription factor screen somehow affects the differentiation capacity of the control cells, which allows one to identify factors that result in an increase in the differentiation capacity. This is supported by the relatively low degree of differentiation of the control cells in* [*Figure 1C*](#fig1){ref-type="fig"} *compared to control cells in* [*Figure 1D*](#fig1){ref-type="fig"}*. This should be clarified in the manuscript. Microscopic pictures of the differentiation capacity of control cells would be valuable for evaluation of the degree of differentiation. Also, based on the Western blotting in S1c, it isn\'t clear what is being overexpressed. Why are there so many HA-tagged products of such varying sizes?*

In our study we used a differentiation protocol without rosiglitazone, which does not result in 100% differentiation of 3T3-L1 cells. We implemented this protocol because we were specifically interested in identifying transcription factors that enhance adipogenesis. If rosiglitazone had been used, then the margin to see this effect would have been very low since PPAR activators such as rosiglitazone yield close to complete differentiation of 3T3-L1 cells (e.g. Chawla and Lazar, PNAS, 1994). With our protocol, the average differentiation of cells was close to 50%, leaving ample room for observing enhancing effects. To be completely clear, but considering the fact that the method has already been described several times in the literature (e.g. Meissburger et al. EMBO Mol Med, 2011; Trajovski & Stoffel, Nat Cell Biol, 2012), we included microscopic images of our differentiation screen in [Author response image 1A](#fig7){ref-type="fig"}. If it is deemed necessary, these images can also be included in the supplementary material of the manuscript*.*Author response image 1.(**A**) Microscopic images of BODIPY (lipids, in green) and Hoechst (nuclei, in red)-stained 3T3-L1 cells transduced with control, ZEB1 and PPARG overexpression constructs. (**B**) Adiponectin levels plotted against fat mass, weight and BMI of obese subjects. Spearman's ρ and p-values are indicated. (**C**) Microscopic images of Oil Red O-stained 3T3-L1 adipocytes after control and ZEB1 KD using three different quantities (measured in terms of µl) of pooled shRNAs at day 6. The relative expression of *Zeb1*, *Pparg* and *Adipoq* at day 2 are shown in the associated bargraphs.

In addition, we have listed the percentage of differentiated cells in response to control vector overexpression in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"} of the revised manuscript*.* Finally, we added clarifying statements to the Materials and methods section of the revised manuscript.

As for the images in [Figure 1C--D](#fig1){ref-type="fig"}, we note that these were not derived from the screen. Here, the differentiation difference results from the fact that panel 1C involves stable cell lines whereas panel 1D involves non-selected cells. We have consistently observed a lower differentiation capacity of stable cell lines compared to cells that are only transiently transduced. The differentiation enhancement (or lack thereof) needs therefore to be evaluated as compared to the stably or transiently transduced controls respectively. As suggested by the reviewers, we have added microscopic images of the cells shown in [Figure 1C--D](#fig1){ref-type="fig"} in two new figures: [Figure 1--figure supplement 2 and 3](#fig1s2 fig1s3){ref-type="fig"} of the revised manuscript and have indicated this in the revised [Figure 1](#fig1){ref-type="fig"} legend.

Regarding the Western blot in [Figure 1--figure supplement 1C](#fig1s1){ref-type="fig"}, several overexpressed TFs yielded indeed multiple HA-tagged products. This is especially the case for ZEB1. However, similar ZEB1 band profiles were also observed in other studies using different endogenous antibodies (Chang et al., Nat Cell Biol, 2001; Gregory et al., Nature Cell Biology, 2008; Wellner et al., Nat Cell Biology, 2009; Masin et al., *Cancer* and Metabolism, 2014). We therefore suspect that these bands reflect cryptic translation or specific protein degradation products given that they stem from the same open-reading frame construct and that they are all tagged by HA. To clarify this, we have added a statement to the revised [Figure 1--figure supplement 1C](#fig1s1){ref-type="fig"} legend.

2\) Effect of ZEB1 knockdown on ZEB1 promoter occupancy. The ChIP-seq for Zeb1 should have a knockdown control. There are a large number of weak peaks, most of which seem not to have the ZEB1 motif. How many of these peaks are still present in the absence of ZEB1?

We already indicated in the original manuscript (Material and methods, Lentiviral production and stable cell lines) that despite extensive efforts, we were unable to derive a stable ZEB1 knockdown 3T3-L1 cell line. This issue renders the negative control experiment suggested by the reviewers rather difficult because of the intrinsic cellular heterogeneity that arises upon transient knockdown. We thus decided to validate our ZEB1 ChIP-seq data by performing a ChIP on HA-tagged ZEB1 in undifferentiated 3T3-L1 cells using a HA-specific antibody to provide the requested assessment of the specificity of the ZEB1 antibody. While overexpression may increase the number of binding events, we would expect the majority of endogenous ZEB1 binding sites to overlap with those detected using ZEB1-HA ChIP. Indeed, we found that ZEB1 replicate experiments versus ZEB1-HA before differentiation showed high correlation of read counts with Spearman's rho = 0.83 and 0.86, in the range of what is typically observed for replicate ChIP-seq experiments (see revised [Figure 3--figure supplement 1B-C](#fig3s1){ref-type="fig"}). A clarifying statement was added in the Results section of the revised manuscript).

In addition, we included in the revised manuscript the ChIP-qPCR results of 12 positive and three negative regions that we had previously used to validate the ZEB1 ChIP-seq libraries. Ten of these 12 positive regions were enriched compared to the negative regions further validating the robustness of the ZEB1 ChIP-seq data (revised [Figure 3--figure supplement 1A](#fig3s1){ref-type="fig"} and the respective qPCR primers were added to the revised Supplementary file 9).

*3) Relationship of ZEB1 and C/EBPb. The authors convincingly show that ZEB1 binds to many chromatin regions together with C/EBPβ and this factor also associates with ZEB1 in a co-IP experiment indicating that these factors cooperate on chromatin. This conclusion would be strengthened if it could be demonstrated that C/EBPβ binding to chromatin is affected by ZEB1 knockdown and vice versa*.

As indicated above, we were unable to derive stable ZEB1 knockdown cells, which makes performing ChIP experiments difficult. We therefore set out to analyze the binding behavior of ZEB1 in stable C/EBPβ knockdown 3T3-L1 cells (revised [Figure 3--figure supplement 2A](#fig3s2){ref-type="fig"}). We selected 10 genomic regions bound by both C/EBPβ and ZEB1 as well as six regions bound by ZEB1 only, using publicly available C/EBPβ ChIP-seq data (Siersbaeck et al., EMBO J, 2011). First, we validated these regions by performing C/EBPβ ChIP-qPCR in control 3T3-L1 cells (revised [Figure 3--figure supplement 2B](#fig3s2){ref-type="fig"}), allowing us to uncover that C/EBPβ binding is more prevalent than so far appreciated ([@bib65], [@bib71]) given that we found that most tested "ZEB1-only" regions (five out of six) are nevertheless bound by C/EBPβ. These results already strengthen the regulatory relationship between ZEB1 and C/EBPβ. We then targeted nine regions that we experimentally determined were bound by both C/EBPβ and ZEB1 as well as the sole ZEB1-only bound region to determine the ZEB1 DNA binding enrichment at these regions in stable C/EBPβ knockdown versus control cells using ZEB1 ChIP-qPCR. We found that ZEB1 DNA binding is decreased to various degrees at all tested regions compared to control knockdown cells, whereas this was not observed at the control site bound by ZEB1 only (revised [Figure 3--figure supplement 2C](#fig3s2){ref-type="fig"}). These results suggest that the binding behavior of ZEB1 is influenced by C/EBPβ, although we cannot exclude at this point that the observed decrease in ZEB1 DNA binding in C/EBPβ knockdown cells may stem from a decrease in overall ZEB1 protein levels. Indeed, further analyses revealed that the knockdown of C/EBPβ in 3T3-L1 cells decreases ZEB1 gene expression, as assessed by qPCR (revised [Figure 3--figure supplement 2D](#fig3s2){ref-type="fig"}). This result implies that C/EBPβ mediates *Zeb1* expression, which is substantiated by the fact that C/EBPβ appears to target the *Zeb1* gene in 3T3-L1 pre-adipocytes (revised [Figure 3--figure supplement 2E](#fig3s2){ref-type="fig"}). Thus, the decreased DNA binding of ZEB1 in C/EBPβ-knockdown cells may also be a consequence of overall decreased ZEB1 levels (even though this was not reflected at the negative control site 10).

Taken together, although further experiments will be required to examine putative DNA binding cooperativity effects between ZEB1 and C/EBPβ, our data clearly demonstrate that ZEB1-C/EBPβ site co-occupancy is even more abundant than previously anticipated and that C/EBPβ may regulate ZEB1 expression, providing further support of the important regulatory relationship between ZEB1 and C/EBPβ. We have added these results to the revised manuscript as a new paragraph in the section "ZEB1 co-binds adipogenic regulatory regions with established early regulators such as C/EBPβ"**,** as well as in the revised [Figure 3--figure supplement 2](#fig3s2){ref-type="fig"}.

*4) Better correlation between gene expression and promoter occupancy. The correlation between ChIP-seq data and gene expression profiles is well documented (*[*Figure 4*](#fig4){ref-type="fig"} *and supplemental information). However, it would be informative if the RNA-seq data upon ZEB1 knock down were included here to make it clear whether genes associated with early, late, or static ZEB1 binding are in fact affected by ZEB1 knock down. The data is already used in* [*Figure 2*](#fig2){ref-type="fig"}*, so it should be straightforward to analyze the effect of knock down on the expression of putative direct ZEB1 target genes identified by ChIP-seq*.

As per the reviewers' suggestion, we have now integrated the RNA-seq data upon ZEB1 knockdown with the dynamic ZEB1 binding data, specifically adding the text below to the section "ZEB1 DNA-binding is dynamic at adipogenic genes" of the revised manuscript as well as revised panels [Figure 4E](#fig4){ref-type="fig"} and [Figure 4--figure supplement 1G](#fig4s1){ref-type="fig"}.

*5) Additional data for the in vivo studies. For the in vivo differentiation of implanted precursor cells, it would be relevant to know whether ZEB1 knockdown affects proliferation of precursor cells, their commitment or just their maturation to adipocytes. Also, data on gene expression would be informative*.

For the *in vivo* experiments, we were unfortunately unable to recover data on gene expression as the adipose tissues were fixed in paraformaldehyde and embedded with paraffin for H&E staining. However, as this specific method has been validated extensively (see e.g. Meissburger et al. EMBO Mol Med, 2011), we are confident that, consistent with our *in vitro* data, the effect observed here clearly demonstrates that ZEB1 is an important regulator of adipogenesis.

However, based on our image analyses, we were able to address the question whether ZEB1 modulation affects cell proliferation, which is a major determinant for adipogenesis. Specifically, we quantified the nuclei from the implant sections and did not observe any change in proliferation in the ZEB1 knockdown or overexpression samples compared to the respective controls, although ZEB1 knockdown tended to yield more variable results (revised [Figure 6--figure supplement 1B](#fig6s1){ref-type="fig"}). These results suggest that the observed effect of ZEB1 on adipogenesis does not involve major changes in the degree of cell proliferation capacity. We have added this result to the "ZEB1 is an important regulator of in vivo adipogenesis" Results section of the revised manuscript.

Finally, we think that addressing the question whether commitment or maturation is affected is still beyond the current state of the art. This is mainly due to the fact that so far no bona fide marker exists to differentiate between cells that can commit to the adipocyte lineage versus committed adipoblasts capable of maturating into an adipocyte.

*6) Clarification of the human data. The human data in Figure 7 is somewhat at odds with prior results. Is adiponectin positively correlated with body weight in these samples? It looks like it might be, which is not generally how those two variables interact*.

While we acknowledge that the correlations presented here might suggest a positive correlation between adiponectin and body weight, this is in fact not the case ([Author response image 1B](#fig7){ref-type="fig"}). It has to be mentioned that the correlation of adiponectin with body weight is seen when comparing lean versus obese individuals. The cohort that we employed in this study consists entirely of obese individuals with a BMI of \>35. Thus, no correlation between adiponectin and body weight was necessarily expected and none was indeed observed.

7\) Claims regarding commitment are premature. A weak point in the manuscript is the data on the importance of ZEB1 for commitment of MSCs to the adipocyte lineage. Although the authors provide evidence that ZEB1 is required for terminal differentiation of MSCs (i.e. C3H10T1/2 cells), it is not clear if this is because ZEB1 is required for the commitment step. The analysis of expression of Zfp423 and Zfp521 upon ZEB1 knock down is not convincing in itself. If the authors want to claim that ZEB1 also regulates commitment, this should be more thoroughly evaluated experimentally. Note, the editor believes that this question is better suited for a future manuscript and strongly suggests that the authors simply soften their conclusions regarding a role in commitment in the present paper. Alternatively, if the authors wish to make this claim, additional studies would be required. Some of the questions that could be addressed include: (1) can over expression of ZEB1 substitute for BMP-2/4 signaling to commit C3H10T1/2 cells to the adipocyte lineage?; (2) does overexpression of ZEB1 decrease the potential of C3H10T1/2 cells to develop into other cell lineages?; (3) is transient overexpression or knock down during commitment enough to enhance or decrease, respectively, differentiation of C3H10T1/2 cells?; or (4) is overexpression or knock down only during terminal differentiation of C3H10T1/2 enough to enhance or inhibit differentiation, respectively?

We acknowledge that our current C3H10T1/2 experiments, while highly suggestive, may not be sufficient to conclusively demonstrate ZEB1's involvement in adipogenic commitment. We therefore have decided to take the editor's advice and to pursue this question in a follow-up study. In the current manuscript, we now present ZEB1's intriguing, positive regulatory effect on adipogenic commitment factors and on C3H10T1/2 adipogenesis in the context of the adipogenic regulatory network. To this end, we have restructured the last two figures, in what we think is a concise and conceptually cohesive way of presenting the mesenchymal stem cell results. Additionally, we have removed "determination" from the Abstract and it now reads "identifying ZEB1 as a central transcriptional component of fat cell differentiation".
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